



Cite this: *Chem. Soc. Rev.*, 2022, 51, 7238

Glycosylated gold nanoparticles in point of care diagnostics: from aggregation to lateral flow

Alexander N. Baker,^a George W. Hawker-Bond,^b Panagiotis G. Georgiou,^a Simone Dedola,^c Robert A. Field^{b,cd} and Matthew I. Gibson^{ib,*,ae}

Current point-of-care lateral flow immunoassays, such as the home pregnancy test, rely on proteins as detection units (e.g. antibodies) to sense for analytes. Glycans play a fundamental role in biological signalling and recognition events such as pathogen adhesion and hence they are promising future alternatives to antibody-based biosensing and diagnostics. Here we introduce the potential of glycans coupled to gold nanoparticles as recognition agents for lateral flow diagnostics. We first introduce the concept of lateral flow, including a case study of lateral flow use in the field compared to other diagnostic tools. We then introduce glycosylated materials, the affinity gains achieved by the cluster glycoside effect and the current use of these in aggregation based assays. Finally, the potential role of glycans in lateral flow are explained, and examples of their successful use given.

Received 5th April 2022

DOI: 10.1039/d2cs00267a

rsc.li/chem-soc-rev

^a Department of Chemistry, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, UK. E-mail: m.i.gibson@warwick.ac.uk

^b Oxford University Clinical Academic Graduate School, John Radcliffe Hospital Oxford, Oxford, OX3 9DU, UK

^c Icen Glycoscience Ltd, Norwich, NR4 7GJ, UK

^d Department of Chemistry and Manchester Institute of Biotechnology, University of Manchester, Manchester M1 7DN, UK

^e Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Gibbet Hill Road, CV4 7AL, Coventry, UK

1. Introduction – point of care

The diagnosis of infectious diseases should be achieved by; determining infection sites, considering patient needs and gaining a microbiological diagnosis. In many cases, however, diagnosis is guided by symptomatic presentation rather than therapeutic approaches as many of these methods can take hours or days to produce a result. Observational approaches alone can in some cases reduce patient outcomes and the injudicious prescribing of broad-spectrum drugs which can contribute to antimicrobial resistance (AMR).¹



Alexander N. Baker

Dr Alexander N. Baker is a research fellow in the Department of Chemistry at the University of Warwick. He completed his MChem (2007), and PhD (2022) in collaboration with Icen Glycoscience at the University of Warwick. Alex's work, in the Gibson group, is focussed on organic and polymer synthesis to design medical diagnostics for low resource settings. His most recent work has developed diagnostic tools

for the rapid detection of COVID-19 in collaboration with NHS partners and Icen Glycoscience. Beyond his research, Alex is a founding fellow of the Warwick Institute of Engagement (WIE).



George W. Hawker-Bond

Dr George W. Hawker-Bond is an Academic Foundation (AFP) doctor at Oxford University Hospitals NHS Foundation Trust and the Oxford University Clinical Academic Graduate School. He obtained his MChem (2017) degree from the University of Warwick, before qualifying in Medicine (MBChB) from Warwick Medical School in 2021. George's main research interests include the interplay between Chemistry and Medicine – with a particular

focus in neuroscience and psychiatry – and medical education. He has also published on the involvement of under-represented groups in clinical trials.




The first point-of-care (POC) diagnostic was developed in 1962 to measure blood glucose levels.² This was followed by the rapid pregnancy test *circa* 1969.^{3,4} Both of these diagnostics revolutionised care: allowing for testing and diagnosis by or with the patient present. In 2011, point-of-care tests (POCT), or “bedside testing” devices were worth \$15 billion USD with a projected increase of 4% per annum.⁵

While there is no accepted definition for point-of-care testing, it can be considered to be rapid testing at, or near to, the point of need that is used to make a medical decision.^{6–9} Current POCT devices include the aforementioned glucose biosensor, dipsticks and lateral flow devices (LFDs);¹⁰ such as Malaria Rapid Diagnostic Tests (MRDTs)¹¹ and pregnancy tests, that separate samples through a solid phase.⁵

Surveys of medical professionals, in relation to POCT, have indicated that sensitivity (> 90%) is considered the most important attribute, followed by a price of less than \$20 USD and a short detection time.¹² This is summarised by the World Health Organisation (WHO) guidelines for the design of POCT in the ASSURED acronym (Fig. 1).¹³

The cost-effectiveness of POCT, compared to traditional laboratory techniques, has been demonstrated in the UK National Health Service (NHS) Health Checks, an early detection tool for cardiovascular disease;¹⁴ a disease which costs the NHS approximately £7 billion GBP per year.¹⁵ The total expected costs (TEC) per completed Health Check was markedly reduced for POCT compared to laboratory techniques – £18 GBP per completed Health Check compared to £25 GBP, respectively, and attendance rates were higher for POCT.¹⁴



Panagiotis G. Georgiou

Panagiotis G. Georgiou is a Marie Curie Early-Stage Research fellow and a PhD student in Chemistry at the University of Warwick. He obtained his BSc in Chemistry (with minor in Biological Chemistry) from the University in Cyprus in 2017. He then pursued an M.Sc. (by Research) in Chemistry at the University of Warwick under the supervision of Professor Rachel K. O'Reilly. His thesis involved the design and preparation of novel nanomaterials by polymerisation-induced self-assembly (PISA) for bio-related applications. He is currently pursuing his PhD at the University of Warwick (UK) under the supervision of Prof. Matthew I. Gibson. His project involves the development of novel nanomaterial biomimetics with advanced properties.



Simone Dedola

Dr Simone Dedola is General R&D Manager at Icen Glycoscience where he leads the chemistry and the assay development team. His specific expertise lies in the chemical synthesis of carbohydrates, total synthesis of glycoproteins, and the chemoenzymatic synthesis of glycoconjugates for vaccine and diagnostic programmes, assay development, in vitro diagnostics. Dr Dedola has experienced the journey from academia to SME, from academic high science to pragmatic SME R&D, he has been with the company from day one (> 6 years) and has a full appreciation of the company's activities, from concept and research through development to product prototyping.



Robert A. Field

Professor Rob Field is Director of the Manchester Institute of Biotechnology, Professor of Chemistry at the University of Manchester, and co-Founder/CSO of Icen Glycoscience. He completed his degree and PhD at the University of East Anglia and went on to postdoctoral work at the University of Oxford (1989–91) followed by the University of Dundee (1992–94). He was appointed to the Chemistry Department (1994) at the University of St Andrews and promoted to full Professor (1999). Following this, he was at the University of East Anglia (2000–06) and the John Innes Centre (2007–19). Rob's research team investigates the chemistry of biological systems, including glycobiology.



Matthew I. Gibson

Professor Matthew I. Gibson holds a personal chair in the Department of Chemistry and also the Medical School at the University of Warwick, UK. Matt completed his Degree (2003) and PhD (2007) at the University of Durham (UK), before post-doctoral research at EPFL (Switzerland). Matt is currently a Royal Society Industry Fellow, ERC Consolidator Grant holder and co-founder of Cryologyx Ltd. Matt's multidisciplinary research group focusses on developing biomaterials to address healthcare challenges. Most recently they have developed tools for COVID-19 diagnostics and polymers to protect biologics during cold storage.



- Affordable** – for those at risk of infection
Sensitive – minimal false negatives
Specific – minimal false positives
User-friendly – minimal steps to carry out
Rapid and robust – short turnaround and easy to store
Equipment-free – no complex equipment
Delivered – to end user

Fig. 1 ASSURED acronym, WHO guidelines for the design of POCT.

It is equally important to consider the perspectives of patients and health care professionals (HCPs) to POCT. During an increase of Dengue fever cases in Singapore, POCT were found to be more convenient, and marginally better than non-POCT in improving the speed and accuracy of diagnoses.¹⁶

The alternative to POC testing is (highly accurate) laboratory-based testing, which require trained staff, embedded health infrastructures and specialised facilities. This makes lab-based methods, considered standard in wealthier nations, cost-prohibitive in low- and middle-income countries. This is evidenced by the COVID-19 (caused by SARS-COV-2) pandemic. PCR-based approaches have been the primary tool for diagnosis but is not ideal for mass testing due to price, turnaround time and the need for centralised infrastructure.^{17,18} It is estimated that laboratory-independent POCT for four common infections (syphilis, malaria, tuberculosis and bacterial pneumonia) could prevent more than 1.2 million deaths per annum in low- and middle-income countries.⁴ Chromatographic lateral flow paper-based immunoassays, as highlighted by MRDTs and pregnancy tests, are of particular interest as POCT because of their low cost, speed of use, laboratory-independence and wide range of devices and analytes currently in use.¹⁹

This review article introduces the potential of glycans (sugars/carbohydrates) to be deployed in rapid, lateral flow assays, compared to the currently used antibody-based LFDs. We first summarise the chemical basis of POC lateral flow immunoassay (LFIA) diagnostics that are based upon antibodies. We then provide a discussion on how a lateral flow assay has been deployed in the real world. Finally, we discuss glycosylated materials, in particular glycosylated gold nanoparticles. We focus on gold particles as these are the basis of commercial tests, however other material cores are highlighted. We cover the rapidly emerging literature showing the development of paper-based lateral flow glyco-assays, LFGA.

2. Lateral flow – an overview

Lateral flow devices (LFDs) typically employ antibodies as sensing components; these devices are often termed lateral flow (immuno) assays (LFIA), or “sol particle immunoassays” as originally termed by Leuvering *et al.*²⁰ LFIAs have been developed for a variety of targets, including; complement;²¹ anabolic steroids;²² prostate-specific antigen;²³ leprosy²⁴ and meningitis²⁵ in serum; evidence of kidney injury in urine;²⁶ *V. cholerae* in faeces;²⁷ and other marker proteins^{28,29} or pathogens³⁰ in whole blood samples.³¹ This ability to target a




Fig. 2 Schematic of a prototypical lateral flow device. (A) Device constituents in a successful positive test and (B) a successful negative test. Generic pregnancy tests for HCG detection inset.

broad range of analytes has led to the use of lateral flow devices in policing illicit drug use, for example.^{32,33}

LFDs typically contain two components; a mobile phase and a stationary phase. When a sample is applied to the strip's sample pad, it is drawn by capillary forces caused by the wick, through the device (Fig. 2A). Then the sample passes through the conjugate pad. If the sample contains the target analyte (Fig. 2Aa), it will bind antibody-coated gold nanoparticles (or other coloured nanomaterials) within the conjugate pad (Fig. 2A). The sample and nanoparticles (both bound and unbound) pass into the nitrocellulose membrane, where they move through two lines of the deposited material. One of these lines is a control line that containing antibodies specific to the primary antibody in the conjugate pad (Fig. 2Ad). Binding of the nanoparticles only to the control line indicates a successful test, but a negative sample (Fig. 2B). The test line contains antibodies specific to the analyte. A line will form if the analyte is “sandwiched” between antibodies immobilised in the test line and antibodies immobilised on the nanoparticles (Fig. 2Ac).

There are examples of multiplexed lateral flow tests.³⁴ This multiplexed approach allows for greater efficiency and greater diagnostic precision and may reduce overall cost when tests are combined into one device. An earlier form of the lateral flow test, called a flow-through assay, utilised an immobilised sample as a test line – these devices are often less sensitive than lateral flow devices. However, they are employed when



lateral flow is not possible for economic or chemical reasons or during the prototyping and the development stages of LFD design.^{5,35}

3. The components of lateral flow

The stationary phase

The stationary (immobile) phase comprises a receptor bound to the surface, usually an antibody. Larger antibodies do not require an immobilisation agent, with immunoglobulin G having an absorption of $> 100 \mu\text{g cm}^{-2}$ on nitrocellulose; however, protein absorption can decrease with decreasing molecular weight.³⁶ Bovine serum albumin (BSA), or less commonly ovalbumin, are used as carriers/immobilisation agents for small molecules such as nucleotides and small proteins.^{19,37} Less common immobilisation strategies include covalent epoxide-thiol and using fusion-proteins.³⁸ Strategies to immobilise polynucleotides have also been reported.^{39,40}

The low absorption of unconjugated antibodies was noted in polymeric systems by Aoyama *et al.*⁴¹ To overcome this they produced high surface area microcone architectures on polycarbonate sheets. The increased surface area enabled high antibody immobilisation levels. This step was inspired by the use of plastic and paper microfluidic systems,⁴² a rapidly growing technique that has been used to sense Ebola virus RNA,⁴³ *Salmonella typhimurium*⁴⁴ and glucose.⁴⁵

Studies with cellulose paper have also exploited biotin and the ability to covalently modify the cellulose surface for easy test line immobilisation.^{46,47} Tanaka *et al.* and Nagatani *et al.* have utilised the localised surface plasmon resonance (LSPR) phenomenon of gold nanoparticles in the stationary phase to enhance the signal-to-noise ratio when sensing for human chorionic gonadotrophin (HCG) and prostate-specific antigen respectively.^{23,48} This approach allowed for detection limits of 1 pg ml^{-1} of HCG,⁴⁸ the hormone detected in the standard pregnancy test.

Reverse immunoassays that utilise “proteinticles” (protein-coated nanoparticles) in the stationary phase have also been developed.⁴⁹ In these systems, antibodies against HIV and hepatitis A and B were tested in the mobile phase. However, the patient’s immune system must mount an adaptive immune response for the test to be successful. Other tests, such as the Epstein-Barr Virus Antibody Test, also sense for an immune response to the pathogen. Although not POC, it does provide precedence for reverse immunoassay approaches.⁵⁰

The mobile phase

Nanoparticles for biosensing have received significant attention due to their unique optical properties, making them ideal for sensing activities,⁵¹ and their tunability in terms of morphology and composition.⁵² Plasmonic, especially gold, particles are the most common signal generating units. Plasmonic nanoparticles are intensely coloured because their free electron density can couple with electromagnetic photons with a wavelength greater than the size of the nanoparticle.^{53–55} The colour

Table 1 Attenuation coefficients of a selection of nanoparticles and dyes

Chromophore	Molar attenuation coefficient (ϵ , $\text{M}^{-1} \text{ cm}^{-1}$)	Wavelength, λ_{MAX} (nm)
Gold nanoparticles, 35 nm ⁵⁹	$\sim 6.1 \times 10^9$	506
Silver nanoparticles, 30 nm ⁶⁰	$\sim 1.5 \times 10^{10}$	406
Sudan III ⁶¹	$\sim 3.0 \times 10^4$	512
Methylene blue ⁶¹	$\sim 4.1 \times 10^4$	654
Crystal violet ⁶¹	$\sim 7.6 \times 10^4$	590
5,10,15,20-tetra-21H-23H-porphine zinc ⁶¹	$\sim 5.7 \times 10^5$	422

of a nanoparticle is not only dependent on its size but also its shape and the dielectric constant of the metal and medium it is in, as shown by the Fröhlich condition.^{56–58} Only light resonant to electron oscillation can excite the localised surface plasmon and be absorbed by it; this absorption leads to localised surface plasmon resonance (LSPR), producing the distinctive colour of the nanoparticle system, which in the case of gold is from red to blue. Plasmonic nanoparticles have high molar attenuation (extinction) coefficients (ϵ), hence their use in LFDs. For example, 35 nm gold nanoparticles (AuNPs) and silver nanoparticles (AgNPs) have attenuation coefficients far higher than common organic dyes such as Sudan III, methylene blue and crystal violet. The best porphyrin dyes, such as 5,10,15,20-tetra-21H-23H-porphine zinc, also have lower attenuation coefficients than AuNPs (Table 1). High attenuation coefficients lead to bright, vivid colours even at low concentrations in nanoparticles systems, making them ideal for sensing applications.

Gold nanoparticles (AuNPs, 15–800 nm) are the most widely used plasmonic particles³¹ due to their biocompatibility, simple synthesis, low cost (at the concentration used) and straightforward functionalisation with organic molecules, particularly thiols. The most common method for AuNP synthesis uses HAuCl₄, and sodium citrate as both a reducing and capping agent.^{62–64} By using seeded growth, anisotropic nanocrystals, such as rods, wires and triangles can be obtained and used in lateral flow systems.⁶⁵

AuNPs can be surface-modified with the analyte targeting components by surface passivation using sulphur-linked (for example, thiols and thioctic acids)⁶⁶ or electrostatically charged antibodies or DNA strands for example.³⁹ Capping ligands include; zwitterions, polymers, peptides, proteins, sugars and nucleic acids (Fig. 3).⁵¹ The vast majority of lateral flow systems utilise antibody capping groups and have been extensively reviewed.^{19,31,37}

In addition to gold, but outside of the scope of this review, other nanoparticles have also been tested in lateral flow systems, including; core-shell gold nanoparticles,⁶⁷ quantum dots,⁶⁸ graphene oxide⁶⁹ and carbon nanotubes.⁷⁰ Furthermore, Dou *et al.* have produced nanomaterial-free antibody systems⁷¹ using crystal violet-stained antibodies, enabling a test to run in 14 minutes.

While many lateral flow devices are designed for qualitative analysis, often by eye, it is possible to quantify analyte concentrations. Urusov *et al.* describe three methods for quantitative






Fig. 3 Schematic of strategies for the functionalisation of nanoparticles for use as the mobile phase in lateral flow devices.

detection; optical detection using a camera, scanner, or smartphone etc and image analysis software, or magnetic labels or electrically conductive labels.⁷² In these methods the intensity of the test line is used as an indication of the analyte concentration, *versus* a calibration curve. The benefits of quantification, as described by Urusov *et al.* include the removal of human subjectivity, a lower limit of detection and an understanding of the target's concentration. However, the use of an additional device for analysis does decrease the applicability of some setups in low-resource scenarios.

The simplicity, diversity and broad applicability to many targets have made lateral flow systems an attractive diagnostic. Many other POCT devices and lab-based diagnostics have been designed for use in more economically developed countries (MEDCs) but are not compatible in less economically developed countries (LEDCs).^{73,74}

4. Malaria rapid diagnostic tests – a case study

MRDTs in the field

Malaria Rapid Diagnostic Tests (MRDTs) have been deployed in low- and middle-income countries as a successful example of the benefits and drawbacks of lateral flow compared to other POC devices. The World Health Organisation (WHO) estimated 438,000 deaths from malaria in 2014, with 90% of these deaths occurring in sub-Saharan Africa (Fig. 4).^{30,75} In 2001, artemisinin-based combination therapies (ACTs) were recommended by WHO as first-line treatments.⁷⁶ Within the decade (2009), resistance to first-line ACT treatments was observed in




Fig. 4 *Plasmodium falciparum* incidence per 1,000 people, 2017.^{88,89} Image produced using The Malaria Atlas Project, (Malaria Atlas Project, <https://malariaatlas.org>, (accessed 6 August 2019)).⁹⁰

the Greater Mekong Sub-region.^{77–79} Resistance to ACTs has not been observed in Africa. However, there is concern that resistance will be observed.^{80,81} During the period from 2008–2015, 35% of suspected malaria cases in Africa were not confirmed with diagnostic tests, which led to antimalarial overuse, increasing the risk of ACT resistance.^{30,81,82} In the same period, resistance was further compounded by broader economic issues. Most malaria-affected countries use treatments costing less than \$0.5 USD per capita, while artemisinin-based combinatorial therapies cost ~\$5 USD per capita.^{83–85} A shift to a diagnostics-led approach could alleviate this problem, with research in Nigerian community pharmacies demonstrating the cost-effectiveness of MRDT-led treatment.⁸⁶ The United Nations Children's Fund (UNICEF) increased its procurement of Malaria Rapid Diagnostic Tests (MRDTs) from 3.8 million tests to 15 million.⁸⁷

MRDTs are POC immunochromatographic or photometric lateral flow devices utilising peripheral blood samples and selenium dyes or AuNPs conjugated to monoclonal antibodies as sensing units, and an example test is shown in Fig. 5.

They are handheld POCT for malaria detection and can differentiate four out of five malaria species (*Plasmodium vivax*, *P. ovale*, *P. malariae* and *P. falciparum*). The devices are,




Fig. 5 Image of negative and positive MRDT, taken from WHO documents.⁹¹



however, insensitive to *P. knowlesi*: a simian parasite known to infect humans. MRDTs target a variety of antigen analytes such as histidine-rich protein 2 (HRP-2 is synthesised by all *P. falciparum* parasites as an abundant water-soluble protein, unlike HRP-1 and HRP-3),⁹² *Plasmodium* lactate dehydrogenase (pLDH) and *Plasmodium* aldolase.^{93,94}

Alternatives to MRDTs and other lateral flow systems

MRDTs are less sensitive than alternative non-POCT techniques, such as microscopy of thick blood films and PCR techniques which can detect low parasite concentrations of 50 parasites per μL and 5 parasites per μL , respectively. While WHO does not test MRDTs at concentrations below 200 parasites per μL .^{30,93} MRDTs are also less capable of determining parasite species beyond *P. falciparum* and *P. vivax*, unlike Giesma-stained blood microscopy,⁹⁵ the most common diagnostic technique, that can have a sensitivity of 95% and a specificity of 98%.^{30,93,96} Furthermore, this high sensitivity and specificity can be achieved at \$0.2 USD per sample at a rate of one sample every 20 minutes.⁹⁶ However, microscopy is a lab-based technique that requires an expert to carry out the analysis, plus the sensitivity can drop to 10% in the field.⁹⁷

Due to the COVID-19 pandemic, diagnostics have been rapidly rolled out globally, with rRT-PCR (real-time reverse transcription-polymerase chain reaction) being the gold standard, but turn-around time can be a limiting factor. In July 2020, in the United States, the average wait time for a COVID-19 RT-PCR test was 4 days, and only 37% of people received results within 2 days.^{98,99} A comparison of rRT-PCR to LFDs showed that lateral flow device sensitivity was > 85% and its specificity > 95%, with a run time of just 15 minutes.¹⁰⁰

Several other techniques have emerged to address the time and cost issues of (the very accurate) rRT-PCRs. Loop-mediated isothermal amplification¹⁰¹ (LAMP) can be run on a benchtop with various outputs generating the signal,^{101,102} in between 20–90 minutes.¹⁰¹ A LAMP device for malaria diagnosis was field-tested in India and Thailand and showed similar sensitivities and specificities to rRT-PCR. LAMP devices have also been developed for SARS-COV-2 and compared well to RT-PCR¹⁰³ and for malaria diagnosis too.¹⁰⁴ Aerts *et al.*,¹⁰⁵ when discussing the cost-effectiveness of LAMP, microscopy and lateral flow tests in diagnosing cutaneous leishmaniasis in Afghanistan, suggested that all these diagnostic platforms have a role to play in different healthcare settings. They found that lateral flow systems reduce overall cost when used outside the clinic. Whereas microscopy is favourable in the clinic except in periods of high demand where LAMP and lateral flow devices are more cost-effective.

MRDT summary

In summary, MRDT lateral flow systems are cost-effective, fast to run and do not require a specialist to perform nor a dedicated laboratory. MRDTs provide an interesting case study in applying POC lateral flow as a low-cost, fast diagnostic *versus* lab-based and more expensive POC systems in LEDCs. Moreover, studies carried out in MEDCs (the United States of

America) have found that MRDTs can outperform blood smear microscopy,¹⁰⁶ showing the potential of lateral flow systems in more economically developed countries where patients and health care professionals value short turnaround times.^{5,12} Therefore, while more expensive reusable POCTs and lab-based diagnostic systems have the potential to provide higher specificities, they do not have the same ease of use, minimal power needs, token maintenance requirements, and low costs of LFDs. It is essential to highlight, though, that some reports of MRDTs suggest they are still costly and challenging to use.¹⁰⁷

Crucially, antibody-based MRDTs can degrade when not transported and stored at low temperatures (“cold-chained”), becoming less-sensitive in conditions common in the field¹⁰⁸ – highlighting a potential weakness of protein-based LFDs and hence there is interest in developing antibody-free lateral flow devices.

5. Beyond antibodies: glycans as recognition units

Current POC diagnostics, particularly lateral flow systems (above), rely on antibodies as recognition units, owing to their high specificity and established methods for their production and nanoparticle conjugation. However, they are not the only biological recognition motifs; nucleic acids¹⁰⁹ and lectins have also been incorporated but are still far less commonly used than antibodies.¹¹⁰ Glycans (carbohydrates) offer an alternative to these recognition units, and their study might bring new opportunities.

Glycans are ubiquitous in biological systems;¹¹¹ with over half of all human proteins glycosylated.¹¹² Glycosylation covalently adds glycans to proteins, lipids or other molecules (including RNA¹¹³) to form glycoconjugates in a dynamic process, regulated by glycosyl transferases and glycosidases.¹¹⁴ As it is not template driven, glycosylation cannot be (readily) predicted from genomic information alone. Glycoconjugates perform a vast range of roles, including; cell signalling,¹¹⁵ hormonal actions,¹¹⁶ cancer progression,¹¹⁷ correct protein folding/structure^{118,119} and mediating immune responses.¹²⁰ Many of these processes occur at the glycocalyx (Fig. 6), found on the surface of eukaryotic and bacterial cells, providing the primary interface for cells with their external environment.¹²¹ The nature of glycan presentation on mammalian cells is a crucial marker of a disease state,^{122,123} influenza species specificity¹²⁴ and influenza A viruses' zoonotic potential.¹²⁵ Antigens from *P. falciparum* have been shown to bind to sialyllactoses and other derivatives found on human erythrocytic glycoprotein A.¹²⁶

Consequently, there is a significant opportunity to target the glycans, or the “glycan-readers” termed lectins, in diagnostics. Lectins are a broad family defined as glycan-binding proteins which are neither enzymes, transporters or antibodies and often have highly conserved carbohydrate-binding domains (CBD).^{128,129} Examples of lectins (or lectin-like proteins) relevant to healthcare include the Shiga toxins,¹³⁰ cholera toxin¹³¹ and ricin,¹³² while also being found in snake venoms¹³³ and






Fig. 6 Electron micrograph of goat coronary capillary stained with Alcian blue and diagrammatic representation of the glycocalyx highlighting glycocalyx functions. Electron micrograph from van den Berg *et al.* reproduced from ref. 127 (Figure 75.1.) with permission from publisher Cambridge University Press, copyright 2007.

biocides in marine algae.¹³⁴ Notably, the use of lectins for staining histology samples has been established for decades.¹²⁸

The use of lectins in biosensor design has been extensively reviewed.^{135,136} For example, Damborský *et al.* have reported a lectin-based LFD for prostate-specific antigen (PSA).¹¹⁰ There is extensive literature on the use of glycans in various applications, which is beyond the scope of this focussed review, but includes; anti-adhesion therapies,^{137,138} glyconanotechnology,^{139,140} antimicrobial applications¹⁴¹ and, influenza¹⁴² and human immunodeficiency virus (HIV)¹⁴³ vaccine development. A challenge (and opportunity) lies in the synthesis of oligosaccharides, which inhabit a vast chemical space beyond that of other biological macromolecules of nucleic acid and protein origin.¹⁴⁴ However, access to glycans for recognition studies is rapidly expanding,¹⁴⁵ thanks to the emergence of automated glycan synthesis^{146–148} and the use of chemo-enzymatic strategies for greater glycan diversification.^{149–151}

Multivalency and glyco-materials

Glycan–lectin interactions are typically weak with K_d (dissociation constants) ranging from mM to μM ,^{139,152} which is significantly weaker than antibody–ligand interactions (in the nM to pM range). This is overcome in Nature by the presentation of multiple copies of glycans leading to statistical rebinding and chelation, resulting in significant enhancements to binding

affinities – known as the “cluster glycoside effect”.^{153,154} The observed affinity enhancement (per glycan) as valency increases is non-linear and is dependent on the architecture of the glycan, its linker and its accessibility to the target. Due to this, there has been significant interest in using materials chemistry (polymers, particles and surfaces) to present multiple copies of glycans. In the context of diagnostic devices, the cluster glycoside effect is crucial to obtaining the necessary affinity and selectivity, which is not possible using individual glycans. To show the power of the cluster glycoside effect, Fig. 7 shows a summary of 37 glycoconjugates from a previous review.¹⁵² This simple representation highlights enhancement effects, ranging from 2 to >10 000-fold increases associated with multivalency. However, it also shows that the simplified assumption that ever larger, higher valency systems lead to increased affinity is not valid: the effects are more subtle. For example, one of the most potent inhibitors of the cholera toxin has just five precisely placed glycans.¹⁵⁵ This is crucial to understand how glycosylated gold (or other) nanoparticles may apply in lateral flow diagnostics and how they can be designed more effectively.




Fig. 7 Graphical representation of a selection of glycoconjugates in “Table 1” from Lundquist *et al.*¹⁵² highlighting the maximum enhancement in binding (corrected for ligand valency) as valency changes.



6. Structural and synthetic strategies for glycan presentation

In order to integrate glycans into nanoparticles for LFDs, it is crucial to consider the synthesis (and glycan-binding potential) of multivalent glycosylated materials, which is essential to generate the needed affinity/avidity. Whilst current LFDs use gold cores, other nanomaterials can be employed, and it is crucial to also consider these routes to multivalency, including polymeric methods. It is important to note that beyond multivalency/presentation on polymeric scaffolds, glycan arrays have allowed the probing of multi-antennary/branched glycans.¹⁵⁶ The benefits of this approach are well illustrated by Wang *et al.*, who synthesised a series of asymmetrically substituted multi-antennary glycans and found differential binding between the structures despite presenting similar terminal sugars.¹⁵⁷

Glycoclusters and dendrimers

Glycoclusters provide well defined and controlled glycan presenting architectures. André *et al.* designed a series of glycoclusters to increase affinity relative to the free sugar and enhance selectivity towards galectins, in some cases more than halving the IC_{50} in a tetravalent arrangement.¹⁵⁸ More complex glycocluster systems have allowed linker length and valency tuning to target virulence factors such as LecA of *Pseudomonas aeruginosa*¹⁵⁹ and the fimbriae-mediated adhesion of *E. coli*,¹⁶⁰ respectively. Other groups have harnessed non-synthetic cores and directed evolution to design glycoclusters.¹⁶¹

Dendrimers are oligomeric or polymeric structures produced iteratively, forming tree-like, highly branched regular structures and have been used as platforms for glycodendrimers.^{162,163} A study by Woller *et al.* measured the binding enhancement realised as dendrimer generation increased in mannose-functionalised dendrimers and saw a 660-fold increase in activity per sugar, *versus* free sugar, when targeting Concanavalin A (ConA).¹⁶⁴ However, glycodendrimers often present a compromise – higher valences are accessible at the cost of decreased structural control and more challenging syntheses, unlike in glycoclusters, where structural control is often favoured over high valences. The high tunability of dendrimers also makes them an attractive approach for sugar presentation, with void spaces in larger dendrimers providing room for molecular cargo, potentially for clinical applications.^{165,166}

Polymeric approaches

Glycopolymers present glycans either on their side chains or end-groups. Due to the relative ease of polymer synthesis, glycopolymers present a convenient route to engineering multivalency.^{167,168} Controlled radical polymerisation techniques have been crucial to glycopolymers development enabling the synthesis of macromolecules with predictable chain lengths, compositions, and architectures – essential to dissect the impact of multivalency. These techniques include atom transfer radical polymerisation (ATRP),¹⁶⁹ reversible addition-fragmentation chain-transfer (RAFT)¹⁷⁰ polymerisation, ring-opening metathesis polymerisation (ROMP)¹⁷¹ and nitroxide-mediated polymerisation (NMP).¹⁷²




Fig. 8 Macromolecular structure to tune cholera toxin binding. (A) control of *cis/trans* backbone;¹⁷⁷ (B) GM-1 mimetic polymer through polymer/glycan linker modifications.^{179,180}

Glycopolymers have been reported (non-exhaustively) to bind with enhanced affinity to lectins and as inhibitors of influenza,^{173,174} to sequester (and inhibit quorum sensing of) bacteria,¹⁷⁵ and to prevent bacterial adhesion.¹⁷⁶ It is emerging how the polymer backbone, which presents the glycans, can itself play a key role in fine-tuning affinity and selectivity. For example, Kiessling showed that *cis*-backbones (from ROMP) in mucin mimetics were more potent inhibitors than *trans* equivalents (Fig. 8A).¹⁷⁷ While amide-linked mannose side-chains were found to bind ConA less than ester-linked side-chains, this difference was attributed to subtle mobility differences.¹⁷⁸

Macromolecular engineering approaches have also been deployed to engineer specificity. For example, side-chain length (*i.e.* linker length between backbone and glycan) was varied to enable control over the access of galactose into the relatively deep GM1 binding pocket of the cholera toxin.^{181,182} While adding branching units on the glycan-polymer linker, the allosteric sialic acid binding site could be targeted to further increase selectivity, Fig. 8B.^{179,180,183} This approach also utilised multiple different glycans within a single polymer chain and was shown to increase affinity through a range of mechanisms¹⁸⁴ beyond just targeting a second binding site – potentially steric shielding too.¹⁸⁵

An alternative approach to increase affinity with heterogeneous glycopolymers was introduced by Mahon *et al.* Polymer-Scaffolded Dynamic Combinatorial Libraries were used to dynamically select for high-affinity pendant groups (Fig. 9).¹⁸⁶

Glycopolymers have been deployed, or show potential for, therapeutic roles and biomedical applications, including enhanced immune responses in vaccine candidates¹⁸⁷ MRI contrast agents,^{188,189} drug delivery,^{190,191} anti-cancer agents¹⁹² and to re-program the glycocalyx.¹⁹³ Chikae *et al.*¹⁹⁴ demonstrated that glycopolymers-coated nanoparticles immobilised on carbon electrodes, can detect amyloid- β , a peptide produced in Alzheimer's disease. Others have shown the






Fig. 9 Dynamic combinatorial selection of avid lectin binders using poly-aldehydes and acylhydrazide glycans.¹⁸⁶

potential of glycopolymer-coated AuNPs as anti-cancer¹⁹⁵ and transfection agents.¹⁹⁶

Each of the above examples shows how the underpinning high-affinity binding from glycopolymers to targets has the potential to be translated into innovative biosensors and diagnostics. The structural versatility of multivalent sugar presenting systems can be used to display a glycan and precisely adjust the nature of the presentation in 3D space¹⁹⁷ (as seen for native glycans) providing opportunities to tune the interaction.

7. Glycosylated gold nanoparticles

As discussed in the previous sections, antibody-functionalised gold nanoparticles are the most common core of lateral flow devices. There is limited literature on glyco-gold nanoparticles for LFD (discussed in the section below), but there is a broad literature on the synthesis and use of glycosylated gold nanoparticles, particularly for lectin binding, which is summarised here. Notably, gold nanoparticles are not the only nanoparticles systems used to detect lectins; examples include quantum dots and magnetic nanoparticles.¹⁹⁸

Whilst many glycosylated nanoparticle syntheses report direct immobilisation, or short linkers to attach the glycan, this can lead to colloidal stability challenges and irreversible aggregation when in biologically relevant media, such as saline buffers or blood plasma. Hence, the use of polymeric tethers that provide steric stabilisation and act as non-fouling¹⁹⁹ interfaces has been explored.

Polymer chains can be added to the surface of AuNPs by three conceptual methods; “grafting to” (a polymer is added to the surface of pre-prepared AuNPs), *in situ* (a polymer is added to the surface of growing AuNPs) and “grafting from” (polymerisation occurs on CTAs or initiators bound to the pre-prepared AuNP surface), Fig. 10.²⁰⁰ The advantage of “grafting to” is that the precursor polymer can be synthesised and characterised, and installation of the glycan (or other functionality) can be confirmed, which is challenging when added directly to a nanoparticle surface. It is, however, important to note that the diffusion of a macromolecule onto the surface and steric constraints limit the grafting density. This is overcome with “grafting from”, which gives high densities, but it must be isolated from the surface to characterise the polymer. Finally *in situ* methods, to produce particles in the presence of a polymeric capping agent, can be used which is a balance between the two other approaches.




Fig. 10 Representation of the three conceptual methods of polymer grafting to a surface.

Poly(ethylene glycol) (PEG) is widely used as a nanoparticle coating due to its low-biofouling, low cytotoxicity and commercial availability. Russel and co-workers used a PEG linker to immobilise a tri-functional sialoside to gold nanoparticles, enabling tuning of avian *versus* human influenza binding (dictated by the 2,3 *versus* 2,6 linkages).²⁰¹ Penadés and co-workers have used PEGylated gold nanoparticles²⁰² to investigate glycosphingolipid mediated carbohydrate-carbohydrate interactions when coupled with an SPR sensor.²⁰³

Whilst PEG is widely used, there are thousands of other potential monomeric building blocks for the polymer tether. RAFT polymerisation has attracted interest in this respect, as it installs an α -terminal (latent) thiol on every chain, which is suitable for immobilisation onto gold surfaces.^{204,205} Cameron and co-workers used poly(galactosides) derived by RAFT for the *in situ* formation of small (<20 nm) glycosylated AuNPs, capable of lectin recognition and to generate glyco-conjugate cancer vaccines.²⁰⁶ RAFT polymerisation has also been used to make pH responsive²⁰⁷ and thermoresponsive²⁰⁸ glycopolymers on AuNPs. Other (non-RAFT) approaches using disulphide, double-headed ATRP initiators²⁰⁹ or “grafting from” methods have also been used.^{210,211} The versatility of these approaches enables a mix and match approach whereby polymer ligands can be applied, and the coated gold nanoparticles are easily isolated by centrifugation/washing cycles (Fig. 11).

8. Glycosylated AuNPs in sensors and diagnostics – from aggregation to lateral flow

Considering the large body of research on the synthesis of glycosylated materials, and integration into (gold) nanomaterials there has been obvious interest in their deployment for diagnostics and biosensing applications, such as colorimetric bioassays.²¹⁸ When nanoparticles become localised, the surface plasmon absorption energy maximum of a plasmonic nanoparticle is altered by collective conduction-band electron oscillation *i.e.* when nanoparticles aggregate there is a strong colour change.^{51,56} Mirkin *et al.*, demonstrated that oligonucleotide-functionalised AuNPs aggregated in the presence of complementary DNA sticky ends






Fig. 11 Major nanoparticle design considerations and common lectin analytes for aggregation assays and potential for use in lateral flow assays. Lectin structures were taken from the Protein Data Bank²¹² as follows; soybean agglutinin (SBA) – 1SBF,²¹³ concanavalin A (ConA) – 3CNA,²¹⁴ cholera toxin (CTX) – 1XTC,²¹⁵ wheat germ agglutinin (WGA) – 2X52²¹⁶ and peanut agglutinin (PNA) – 2DVD.²¹⁷

showing how specific DNA sequences can be identified by a simple colour change in solution.²¹⁹ Due to the fact that lectins often have multiple binding sites (*i.e.* Concanavalin A (ConA) has 4,²²⁰ Soybean agglutinin (SBA) has 4),²²¹ multivalent glycosylated gold nanoparticles have been explored as colourimetric sensors for lectins based on red-blue colour shifts.

Many studies have focused on model (plant) lectins, such as G-rutin functionalised AuNPs (*via* a catechol) or mannosylated polymers to bind ConA,^{222,223} galactose-functionalised glycopolymers to bind *Ricinus communis* agglutinin I (RCAI or RCA₁₂₀),²²³ galactose-functionalised glycopolymers made by copper-free click immobilised on core-shell AuNPs to bind peanut agglutinin (PNA)^{224,225} and lactose-functionalised glycopolymers to bind cholera toxin.²²⁶ By using polymeric linkers, nanoparticle (steric) stability in complex media is introduced, avoiding false positives and unwanted aggregation which can occur with direct-surface conjugation.²²⁷ The use of polymer tethers also enables additional functionality and properties, such as thermal control of glycan presentation.²²⁸

Toyoshima *et al.*²²⁹ synthesised variable density mannose- and *N*-acetylglucosamine-functionalised glycopolymers immobilised on 15, 40 and 100 nm AuNPs. Aggregation experiments were carried out with target and off-target lectins. The mannose functionalised AuNPs were assayed against ORN178 (an *E. coli*

species specific for α -mannose) and aggregated.²²⁹ While Richards *et al.* showed how fimbriae-differing phenotypes (FimH⁺ and FimH⁻) of *E. coli* can be discriminated by glycosylated AuNPs.²³⁰

Aggregation is a crucial consideration of lateral flow (below) but the use of gold nanoparticles for SERS (Surface enhanced Raman scattering) for other device formats is also possible but is beyond the scope of this review. SERS has been demonstrated,²³¹ for example, for both ConA²³² (to pM levels) and human galectins.²³³

Lateral flow

Despite the above, showing the significant body of literature on how multivalent presentation of glycans leads to large binding responses with glycosylated nanoparticles, the incorporation of these into lateral flow glyco-assays (LFGAs) has not been widely explored yet. As glycans can be chemically synthesised, there is no need to raise antibodies against emergent pathogens and the sheer range of tools to alter their presentation make them appealing targets. However, thus far there have been few examples of lateral flow glyco-assays, at the time of writing and to the best of our knowledge, this review covers all published examples (November 2021).






Fig. 12 (A) Representative structure of glycosylated acrylamide coated AuNPs used by Toyoshima *et al.*²³⁴ and Ishii *et al.*²³⁵ (B) Schematic of the flow-through dipstick used by Toyoshima *et al.*²³⁴ and (C) Schematic of the lateral flow dipstick used by Ishii *et al.*²³⁵

Toyoshima *et al.*²³⁴ utilised α -galactose- and α -mannose-*p*-acrylamidophenyl pyranosides against lectins in aggregation assays and surface plasmon resonance (SPR) Fig. 12(A). In this work, however, they also showed a flow-through assay, where Shiga toxin-1 was deposited as the test line, facilitating some binding against the galacto-AuNPs Fig. 12(B). This was taken further by Mirua and co-workers using manno-AuNPs to detect ConA. In this case, the glyconanoparticles were used in the mobile phase and a rabbit anti-ConA antibody as the stationary phase test line Fig. 12(C). The dipsticks gave a visible 'red line' response to the naked eye. Whilst not a full glyco lateral flow, this study clearly demonstrated that glycoLFDs are possible.²³⁵ Further studies varied the mannose density providing optimisation of the output signal.²³⁶ A key learning point from this work, is the challenge of maintaining a good signal-to-noise ratio in the final device, with smearing of the nanoparticles as they run up the nitrocellulose due to non-specific interactions. This shows how the tuning of the polymer coating is essential alongside the use of conventional blocking agents such as BSA, to reduce non-specific interactions. The importance of the polymer coating has previously been observed in aggregation assays where a compromise must be reached between stability in aqueous media and rapid optical readout, usually tuned by adjusting polymer length.^{227,230} Similarly, alterations to the polymer itself *i.e.*, to a more sterically bulky polymer can be used to stabilise AuNPs²³⁷ and favour binding but avoid aggregation.²³⁸

Baker *et al.*, reported that SARS-COV-2 (the causative agent of COVID-19) spike protein has affinity towards certain sialic acids,²³⁹ (confirmed with microarrays²⁴⁰ and STD NMR²⁴¹) discovered using glycosylated nanoparticles against spike protein immobilised on a biolayer interferometry sensor. *N*-Acetylneuraminic acid functionalised poly(hydroxyethyl acrylamide) were immobilised onto AuNPs and were used to detect a




Fig. 13 Representative lateral flow glyco-assay and flow through glyco-assay for sensing for SBA²⁴⁵ (A) and SARS-COV-2²⁴² (B) respectively.

SARS-COV-2 spike protein bearing pseudovirus in what was the first report of a complete lateral flow glyco-assay device (using a BSA-glycoconjugate test-line).²³⁹ This was developed further into a flow-through device, whereby viral samples from patient swabs were dried as the test line, so no glycan test line was needed, allowing correct identification of positive/negative patients (Fig. 13A).²⁴²

Controlled radical polymerisation (RAFT) was employed to undertake a detailed structure-function study exploring how the polymeric glyco tether impacted the performance of a lectin-detecting lateral flow system.²⁴³ Using galactose as the glyco-ligand, the delicate balance between polymer chain



length to give specificity, but avoid non-specific binding was revealed, demonstrated by differential binding profiles to SBA and RCA120 using the same glycan on different polymers (Fig. 13A).

Further work has also been carried out by Baker *et al.* to remove proteins from all sensing components of an LFD *i.e.*, no protein in the test line or on the particle surface. They did this by using poly(vinyl pyrrolidone) anchors decorated with glycans.²⁴⁴ This was further developed by Kim *et al.* who used glycosaminoglycans from the glycocalyx, to make a protein-free test line for SARS-COV-2.²⁴⁵ This approach of using non-protein-based polymers, both synthetic and biological, to present sugars marks a step change in LFD development and could lead to improved workflows.

9. Conclusions and perspectives

The purpose of this review was to introduce lateral flow diagnostic technology, including its chemical basis, and the real-world application of these devices as low-cost diagnostic tools. We then set out to show that rather than just considering these as immuno-assays, with antibodies as the detection systems, that glyco-assays are also possible by exploiting the diverse range of biochemical interactions driven by glycans. Whilst this is a very new field, with less than 10 publications, this makes it the ideal time to introduce the topic, and in particular highlight the key considerations of multivalent presentation and the importance of how glycans are tethered to the nanoparticle (*e.g.* gold) core. The potential for glycopolymer-functionalised AuNPs (or other cores) integrated into lateral flow systems, for use as POCT devices is vast, underpinned by the fast-growing field of glycomics. These low-cost, yet potentially robust glycopolymer-based lateral flow diagnostic devices could be ideal for low- and middle-income, and more economically developed countries alike.

As this is a new and exciting interdisciplinary area, spanning materials chemistry, analytical science, biochemistry, and biomedicine there exist several “challenge areas”, or areas where continued scientific exploration is needed to drive the field forward.

- The integration of new core materials, not just those based on gold or plasmonic nanoparticles.
- A greater understanding of how the linker interface impacts the performance of devices and in particular to reduce non-specific binding.
- The development of chemical tools to integrate glycans into particles more efficiently and at scale, including increasing access to rarer (often low quantity) glycans, alongside the development of the corresponding analytical tools.
- Greater integration of multiple recognition modalities and further development of multiplexed tests.
- The integration of glycan-based sensing into the various ‘flavours’ of lateral flow, or flow-through devices. (Fig. 14) both as all glyco systems, or in combination (“hybrid”) with antibodies, nanobodies, nucleic acids or other small molecule binders.




Fig. 14 Range of lateral-flow and related assays classes highlighting the stationary phase (SP) test line and mobile phase (MP). (A) Flow-through immunoassay (SP – analyte & MP – antibody-coated AuNP); (B) Lateral flow immunoassay (SP – antibody & MP – antibody-coated AuNP and analyte); (C) Flow-through glyco-assay (SP – analyte & MP – glycan-coated AuNP); (D) Hybrid lateral flow immuno-glyco-assay (SP – antibody & MP – glycan-coated AuNP and analyte); (E) Lateral flow glyco-assay (SP – glycan-functionalised test line & MP – glycan-coated AuNP and analyte).

- The demonstration of function in clinically relevant situations and settings, including in complex media.
- Ensuring the devices are sufficiently sensitive and specific to be deployed for real world applications.

In summary, we have introduced the concept of lateral flow glyco-assays and their chemical basis, whilst laying out potential areas of application and the role of chemistry in developing these. It is the hope of the authors that lateral flow glyco-assays will become useful in the coming years, especially in resource-limited settings.

Literature review methods

A review of the literature was carried out to find papers containing AuNP aggregation assays and glycopolymer use in lateral flow assays.

A review of the literature was conducted through the following databases: Web of Science (all years), Embase (1947–2021) and Scopus (all years). Search date November 2021.

The following search terms were used:

Search 1: ((gold AND nanoparticle*) OR (AuNP*)) AND glycopolymer* AND (aggregat* OR surfac*).

Search 2: (“lateral flow” OR assay*) AND glycopolymer*.



Search 3: (((gold AND nanoparticle*) OR (AuNP*)) AND glycopolymer* AND (aggregat* OR surfac*)) AND (“lateral flow” OR assay*) AND glycopolymer*).

Search 1 returned 132 results (Embase 17, Scopus 28, Web of Science 87).

Search 2 returned 632 results (Embase 166, Scopus 221, Web of Science 245).

Search 3 returned 17 results (Embase 2, Scopus 6, Web of Science 9).

Abstracts and full-texts were screened to determine relevant reports in the literature.

Conflicts of interest

RF is a shareholder and director of Icen Glycoscience limited. ANB and MIG are named inventors on a patent relating to underpinning technology reported here.

Acknowledgements

This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement n° 866056) and under the Marie Skłodowska-Curie grant agreement No. 814236. MIG is supported by a Royal Society (Industry Fellowship 191037). This research was funded in whole or in part by the BBSRC [BB/M01116X/1]. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. This work was also supported by Icen Glycoscience. Electron micrograph reproduced from van den Berg *et al.*¹²⁷ (figure 75.1.) under licence from Cambridge University Press, PLSclear Ref No: 53530

References

- 1 S. Leekha, C. L. Terrell and R. S. Edson, General Principles of Antimicrobial Therapy, *Mayo Clin. Proc.*, 2011, **86**(2), 156–167.
- 2 L. C. Clark and C. Lyons, Electrode Systems for Continuous Monitoring in Cardiovascular Surgery, *Ann. N. Y. Acad. Sci.*, 1962, **102**, 29–45.
- 3 M. M. Crane and M. V. Organon, *Diagnostic Test Device*, US3579306A, 1969.
- 4 P. K. Drain, E. P. Hyle, F. Noubary, K. A. Freedberg, D. Wilson, W. R. Bishai, W. Rodriguez and I. V. Bassett, Diagnostic Point-of-Care Tests in Resource-Limited Settings, *Lancet Infect. Dis.*, 2014, **14**, 239–249.
- 5 A. St John and C. P. Price, Point-of-Care Testing Technologies Existing and Emerging Technologies for Point-of-Care Testing, *Clin. Biochem. Rev.*, 2014, **35**(3), 155–167.
- 6 C. P. Price; A. St John and J. Hicks, *Point-of-Care Testing*, American Association for Clinical Chemistry, Washington D.C., 2nd edn, 2004.
- 7 S. S. Ehrmeyer and R. H. Laessig, Point-of-Care Testing, Medical Error, and Patient Safety: A 2007 Assessment, *Clin. Chem. Lab. Med.*, 2007, **No. 45**, 766–773.
- 8 N. P. Pai, C. Vadnais, C. Denkinger, N. Engel and M. Pai, Point-of-Care Testing for Infectious Diseases: Diversity, Complexity, and Barriers in Low-And Middle-Income Countries The Promise of Point-of-Care Testing, *PLoS Med.*, 2012, **9**(9), e1001306.
- 9 N. P. Pai and M. Pai, Point-of-Care Diagnostics for HIV and Tuberculosis: Landscape, Pipeline, and Unmet Needs, *Discovery Med.*, 2012, **13**, 34–45.
- 10 H. Hsieh, J. Dantzler and B. Weigl, Analytical Tools to Improve Optimization Procedures for Lateral Flow Assays, *Diagnostics*, 2017, **7**(2), 29.
- 11 T. Liang, R. Robinson, J. Houghtaling, G. Fridley, S. A. Ramsey and E. Fu, Investigation of Reagent Delivery Formats in a Multivalent Malaria Sandwich Immunoassay and Implications for Assay Performance, *Anal. Chem.*, 2016, **88**(4), 2311–2320.
- 12 Y.-H. Hsieh, C. A. Gaydos, M. T. Hogan, O. M. Uy, J. Jackman, M. Jett-Goheen, A. Albertie, D. T. Dangerfield, C. R. Neustadt, Z. S. Wiener and A. M. Rompalo, What Qualities Are Most Important to Making a Point of Care Test Desirable for Clinicians and Others Offering Sexually Transmitted Infection Testing?, *PLoS One*, 2011, **6**(4), e19263.
- 13 C. S. Kosack, A.-L. Page and P. R. Klatser, Bulletin of the World Health Organization: A Guide to Aid the Selection of Diagnostic Tests, 2017.
- 14 A. El-Osta, M. Woringer, E. Pizzo, T. Verhoef, C. Dickie, M. Z. Ni, J. R. Huddy, M. Soljak, G. B. Hanna and A. Majeed, Does Use of Point-of-Care Testing Improve Cost-Effectiveness of the NHS Health Check Programme in the Primary Care Setting? A Cost-Minimisation Analysis, *BMJ Open*, 2017, **7**(8), e015494.
- 15 P. Bhatnagar, K. Wickramasinghe, J. Williams, M. Rayner and N. Townsend, The Epidemiology of Cardiovascular Disease in the UK 2014, *Heart*, 2015, **101**(15), 1182–1189.
- 16 Q. Tan, Z. J. L. Hildon, S. Singh, J. Jing, T. L. Thein, R. Coker, H. J. M. Vrijhoef and Y. S. Leo, Comparing Patient and Healthcare Worker Experiences during a Dengue Outbreak in Singapore: Understanding the Patient Journey and the Introduction of a Point-of-Care Test (POCT) toward Better Care Delivery, *BMC Infect. Dis.*, 2017, **17**(1), 503–519.
- 17 Z. Li, Y. Yi, X. Luo, N. Xiong, Y. Liu, S. Li, R. Sun, Y. Wang, B. Hu, W. Chen, Y. Zhang, J. Wang, B. Huang, Y. Lin, J. Yang, W. Cai, X. Wang, J. Cheng, Z. Chen, K. Sun, W. Pan, Z. Zhan, L. Chen and F. Ye, Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis, *J. Med. Virol.*, 2020, jmv.25727.
- 18 G. Kolifarhood, M. Aghaali, H. Mozafar Saadati, N. Taherpour, S. Rahimi, N. Izadi and S. S. Hashemi Nazari, Epidemiological and Clinical Aspects of COVID-19; a Narrative Review, *Arch. Acad. Emerg. Med.*, 2020, **8**(1), e41.



- 19 G. A. Posthuma-Trumpie, J. Korf and A. Van Amerongen, Lateral Flow (Immuno)Assay: Its Strengths, Weaknesses, Opportunities and Threats. A Literature Survey, *Anal. Bioanal. Chem.*, 2009, **393**(2), 569–582.
- 20 J. H. W. Leuvers, P. J. H. M. Thal, M. Waart and A. H. W. M. van der; Schuur, Sol Particle Immunoassay (SPIA), *J. Immunoassay*, 1980, **1**(1), 77–91.
- 21 E. C. Schramm, N. R. Staten, Z. Zhang, S. S. Bruce, C. Kellner, J. P. Atkinson, V. C. Kyttaris, G. C. Tsokos, M. Petri, E. Sander Connolly and P. K. Olson, A Quantitative Lateral Flow Assay to Detect Complement Activation in Blood, *Anal. Biochem.*, 2015, **477**, 78–85.
- 22 L. Liu, C. Peng, Z. Jin and C. Xu, Development and Evaluation of a Rapid Lateral Flow Immunochromatographic Strip Assay for Screening 19-Nortestosterone, *Biomed. Chromatogr.*, 2007, **21**(8), 861–866.
- 23 N. Nagatani, T. Yuhi, M. Chikae, K. Kerman, T. Endo, Y. Kobori, M. Takata, H. Konaka, M. Namiki, H. Ushijima, Y. Takamura and E. Tamiya, A Sensitive Immunochromatographic Assay Using Gold Nanoparticles for the Semi-quantitative Detection of Prostate-Specific Antigen in Serum, *Nanobiotechnology*, 2006, **2**(3–4), 79–86.
- 24 S. Buhner-Sekula, H. L. Smits, G. C. Gussenhoven, J. van Leeuwen, S. Amador, T. Fujiwara, P. R. Klatser and L. Oskam, Simple and Fast Lateral Flow Test for Classification of Leprosy Patients and Identification of Contacts with High Risk of Developing Leprosy, *J. Clin. Microbiol.*, 2003, **41**(5), 1991–1995.
- 25 J. N. Jarvis, A. Percival, S. Bauman, J. Pelfrey, G. Meintjes, G. N. Williams, N. Longley, T. S. Harrison and T. R. Kozel, Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine from Patients with HIV-Associated Cryptococcal Meningitis, *Clin. Infect. Dis.*, 2011, **53**, 1019–1023.
- 26 V. S. Vaidya, G. M. Ford, S. S. Waikar, Y. Wang, M. B. Clement, V. Ramirez, W. E. Glaab, S. P. Troth, F. D. Sistare, W. C. Prozialeck, J. R. Edwards, N. A. Bobadilla, S. C. Mefferd and J. V. Bonventre, A Rapid Urine Test for Early Detection of Kidney Injury, *Kidney Int.*, 2009, **76**, 108–114.
- 27 A.-L. Page, K. P. Alberti, V. Mondonge, J. Rauzier, M.-L. Quilici and P. J. Guerin, Evaluation of a Rapid Test for the Diagnosis of Cholera in the Absence of a Gold Standard, *PLoS One*, 2012, **7**(5), e37360.
- 28 S. H. Ang, M. Rambeli, T. M. Thevarajah, Y. B. Alias and S. M. Khor, Quantitative, Single-Step Dual Measurement of Hemoglobin A1c and Total Hemoglobin in Human Whole Blood Using a Gold Sandwich Immunochromatographic Assay for Personalized Medicine, *Biosens. Bioelectron.*, 2016, **No. 78**, 187–193.
- 29 R. E. Biagini, D. L. Sammons, J. P. Smith, B. A. MacKenzie, C. A. F. Striley, J. E. Snawder, S. A. Robertson and C. P. Quinn, Rapid, Sensitive, and Specific Lateral-Flow Immunochromatographic Device to Measure Anti-Anthrax Protective Antigen Immunoglobulin G in Serum and Whole Blood, *Clin. Vaccine Immunol.*, 2006, **12**, 541–546.
- 30 World Health Organisation, Malaria Rapid Diagnostic Test Performance: Summary Results of WHO Product Testing of Malaria RDTs: Rounds 1–6 (2008–2015), 2015.
- 31 R. Banerjee and A. Jaiswal, Recent Advances in Nanoparticle-Based Lateral Flow Immunoassay as a Point-of-Care Diagnostic Tool for Infectious Agents and Diseases, *Analyst*, 2018, pp. 1970–1996.
- 32 S. Gentili, R. Solimini, R. Tittarelli, G. Mannocchi and F. P. Busardò, A Study on the Reliability of an On-Site Oral Fluid Drug Test in a Recreational Context, *J. Anal. Methods Chem.*, 2016, 1–10.
- 33 T. R. Arkell, R. C. Kevin, J. Stuart, N. Lintzeris, P. S. Haber, J. G. Ramaekers and I. S. McGregor, Detection of Δ^9 THC in Oral Fluid Following Vaporized Cannabis with Varied Cannabidiol (CBD) Content: An Evaluation of Two Point-of-collection Testing Devices, *Drug Test. Anal.*, 2019, **11**(10), 1486–1497.
- 34 L. Huang, S. Tian, W. Zhao, K. Liu, X. Ma and J. Guo, *Multiplexed Detection of Biomarkers in Lateral-Flow Immunoassays*, The Royal Society of Chemistry, 2020, vol. 145, pp. 2828–2840.
- 35 M. Z. Zheng, J. L. Richard and J. Binder, A Review of Rapid Methods for the Analysis of Mycotoxins, *Mycopathologia*, 2006, **161**(5), 261–273.
- 36 M. A. Mansfield, Nitrocellulose Membranes for Lateral Flow Immunoassays: A Technical Treatise, *In Lateral Flow Immunoassay*, 2009, pp. 95–114.
- 37 E. B. Bahadır and M. K. Sezginürk, Lateral Flow Assays: Principles, Designs and Labels, *TrAC, Trends Anal. Chem.*, 2016, 286–306.
- 38 C. A. Holstein, A. Chevalier, S. Bennett, C. E. Anderson, K. Keniston, C. Olsen, B. Li, B. Bales, D. R. Moore, E. Fu, D. Baker and P. Yager, Immobilizing Affinity Proteins to Nitrocellulose: A Toolbox for Paper-Based Assay Developers, *Anal. Bioanal. Chem.*, 2016, **408**(5), 1335–1346.
- 39 M. Hiratsuka, A. Ebisawa, Y. Matsubara, S. Kure, Y. Konno, T. Sasaki and M. Mizugaki, Genotyping of Single Nucleotide Polymorphisms (SNPs) Influencing Drug Response by Competitive Allele-Specific Short Oligonucleotide Hybridization (CASSOH) with Immunochromatographic Strip, *Drug Metab. Pharmacokinet.*, 2004, **19**(4), 303–307.
- 40 J. J. Storhoff, R. Elghanian, R. C. Mucic, C. A. Mirkin and R. L. Letsinger, One-Pot Colorimetric Differentiation of Polynucleotides with Single Base Imperfections Using Gold Nanoparticle Probes, *J. Am. Chem. Soc.*, 1998, **120**(9), 1959–1964.
- 41 S. Aoyama, Y. Akiyama, K. Monden, M. Yamada and M. Seki, Thermally Imprinted Microcone Structure-Assisted Lateral-Flow Immunoassay Platforms for Detecting Disease Marker Proteins, *Analyst*, 2019, **144**(5), 1519–1526.
- 42 A. H. C. Ng, U. Uddayasankar and A. R. Wheeler, Immunoassays in Microfluidic Systems, *Anal. Bioanal. Chem.*, 2010, **397**(3), 991–1007.
- 43 L. Magro, B. Jacquelin, C. Escadafal, P. Garneret, A. Kwasiborski, J.-C. Manuguerra, F. Monti, A. Sakuntabhai,



- J. Vanhomwegen, P. Lafaye and P. Tabeling, Paper-Based RNA Detection and Multiplexed Analysis for Ebola Virus Diagnostics, *Sci. Rep.*, 2017, **7**(1), 1347.
- 44 M. Srisa-Art, K. E. Boehle, B. J. Geiss and C. S. Henry, Highly Sensitive Detection of Salmonella Typhimurium Using a Colorimetric Paper-Based Analytical Device Coupled with Immunomagnetic Separation, *Anal. Chem.*, 2018, **90**(1), 1035–1043.
- 45 E. Gabriel, P. Garcia, F. Lopes and W. Coltro, Paper-Based Colorimetric Biosensor for Tear Glucose Measurements, *Micromachines*, 2017, **8**(4), 104.
- 46 K. Kaneko, M. Hara, T. Nishino and T. Maruyama, One-Step Biotinylation of Cellulose Paper by Polymer Coating to Prepare a Paper-Based Analytical Device, *Anal. Chem.*, 2020, **92**(2), 1978–1987.
- 47 A. Yu, J. Shang, F. Cheng, B. A. Paik, J. M. Kaplan, R. B. Andrade and D. M. Ratner, Biofunctional Paper via the Covalent Modification of Cellulose, *Langmuir*, 2012, **28**(30), 11265–11273.
- 48 R. Tanaka, T. Yuhi, N. Nagatani, T. Endo, K. Kerman, Y. Takamura and E. Tamiya, A Novel Enhancement Assay for Immunochromatographic Test Strips Using Gold Nanoparticles, *Anal. Bioanal. Chem.*, 2006, **385**(8), 1414–1420.
- 49 J.-H. Lee, H. S. Seo, J.-H. Kwon, H.-T. Kim, K. C. Kwon, S. J. Sim, Y. J. Cha and J. Lee, Multiplex Diagnosis of Viral Infectious Diseases (AIDS, Hepatitis C, and Hepatitis A) Based on Point of Care Lateral Flow Assay Using Engineered Proteinticles, *Biosens. Bioelectron.*, 2015, **69**, 213–225.
- 50 M. De Paschale, Serological Diagnosis of Epstein-Barr Virus Infection: Problems and Solutions, *World J. Virol.*, 2012, **1**(1), 31.
- 51 P. D. Howes, R. Chandrawati and M. M. Stevens, Colloidal Nanoparticles as Advanced Biological Sensors, *Science*, 2014, **346**(6205), 53–66.
- 52 E. C. Dreaden, A. M. Alkilany, X. Huang, C. J. Murphy and M. A. El-Sayed, The Golden Age: Gold Nanoparticles for Biomedicine, *Chem. Soc. Rev.*, 2012, 2740–2779.
- 53 E. Roduner, Size Matters: Why Nanomaterials Are Different, *Chem. Soc. Rev.*, 2006, **35**, 583–592.
- 54 G. Mie, Beiträge Zur Optik Trüber Medien, Speziell Kolloidaler Metallösungen, *Ann. Phys.*, 1908, **330**(3), 377–445.
- 55 M. X. Faraday, The Bakerian Lecture. —Experimental Relations of Gold (and Other Metals) to Light, *Philos. Trans. R. Soc. London*, 1857, **147**, 145–181.
- 56 S. Eustis and M. A. El-Sayed, Why Gold Nanoparticles Are More Precious than Pretty Gold: Noble Metal Surface Plasmon Resonance and Its Enhancement of the Radiative and Nonradiative Properties of Nanocrystals of Different Shapes, *Chem. Soc. Rev.*, 2006, **35**, 209–217.
- 57 V. Amendola, R. Pilot, M. Frascioni, O. M. Maragò and M. A. Iati, Surface Plasmon Resonance in Gold Nanoparticles: A Review, *J. Phys.: Condens. Matter*, 2017, **29**(20), 203002.
- 58 U. Kreibitz and M. Vollmer, *Optical Properties of Metal Clusters; Springer Series in Materials Science*, Springer Berlin Heidelberg, Berlin, Heidelberg, 1995, vol. 25.
- 59 X. Liu, M. Atwater, J. Wang and Q. Huo, Extinction Coefficient of Gold Nanoparticles with Different Sizes and Different Capping Ligands, *Colloids Surf., B*, 2007, **58**(1), 3–7.
- 60 D. Paramelle, A. Sadovoy, S. Gorelik, P. Free, J. Hobley and D. G. Fernig, A Rapid Method to Estimate the Concentration of Citrate Capped Silver Nanoparticles from UV-Visible Light Spectra, *Analyst*, 2014, **139**(19), 4855–4861.
- 61 M. Taniguchi and J. S. Lindsey, Database of Absorption and Fluorescence Spectra of >300 Common Compounds for Use in PhotochemCAD, *Photochem. Photobiol.*, 2018, **94**(2), 290–327.
- 62 J. Turkevich, P. C. Stevenson and J. Hillier, A Study of the Nucleation and Growth Processes in the Synthesis of Colloidal Gold, *Discuss. Faraday Soc.*, 1951, **11**, 55.
- 63 C. Ziegler and A. Eychmüller, Seeded Growth Synthesis of Uniform Gold Nanoparticles with Diameters of 15–300 Nm, *J. Phys. Chem. C*, 2011, **115**(11), 4502–4506.
- 64 N. G. Bastús, J. Comenge and V. Puntes, Kinetically Controlled Seeded Growth Synthesis of Citrate-Stabilized Gold Nanoparticles of up to 200 Nm: Size Focusing versus Ostwald Ripening, *Langmuir*, 2011, **27**(17), 11098–11105.
- 65 M. Venkataramasubramani and L. Tang, Development of Gold Nanorod Lateral Flow Test for Quantitative Multi-Analyte Detection. In IFMBE Proceedings; 2009, pp. 199–202.
- 66 R. Karamanska, B. Mukhopadhyay, D. A. Russell and R. A. Field, Thioctic Acid Amides: Convenient Tethers for Achieving Low Nonspecific Protein Binding to Carbohydrates Presented on Gold Surfaces, *Chem. Commun.*, 2005, 3334.
- 67 X. Lu, T. Mei, Q. Guo, W. Zhou, X. Li, J. Chen, X. Zhou, N. Sun and Z. Fang, Improved Performance of Lateral Flow Immunoassays for Alpha-Fetoprotein and Vanillin by Using Silica Shell-Stabilized Gold Nanoparticles, *Mikrochim. Acta*, 2018, **186**(1), 2.
- 68 J. Wu, J. Ma, H. Wang, D. Qin, L. An, Y. Ma, Z. Zheng, X. Hua, T. Wang and X. Wu, Rapid and Visual Detection of Benzothiostrubin Residue in Strawberry Using Quantum Dot-Based Lateral Flow Test Strip, *Sens. Actuators, B*, 2019, **283**, 222–229.
- 69 L. Yu, P. Li, X. Ding and Q. Zhang, Graphene Oxide and Carboxylated Graphene Oxide: Viable Two-Dimensional Nanolabels for Lateral Flow Immunoassays, *Talanta*, 2017, **165**, 167–175.
- 70 L. Yao, J. Teng, M. Zhu, L. Zheng, Y. Zhong, G. Liu, F. Xue and W. Chen, MWCNTs Based High Sensitive Lateral Flow Strip Biosensor for Rapid Determination of Aqueous Mercury Ions, *Biosens. Bioelectron.*, 2016, **85**, 331–336.
- 71 L. Dou, T. Bu, W. Zhang, B. Zhao, Q. Yang, L. Huang, S. Li, C. Yang, J. Wang and D. Zhang, Chemical-Staining Based Lateral Flow Immunoassay: A Nanomaterials-Free and Ultra-Simple Tool for a Small Molecule Detection, *Sens. Actuators, B*, 2019, **279**, 427–432.
- 72 A. E. Urusov, A. v Zherdev and B. B. Dzantiev, Towards Lateral Flow Quantitative Assays: Detection Approaches, *Biosensors*, 2019, **9**(3), 89.



- 73 R. W. Peeling and D. Mabey, Point-of-Care Tests for Diagnosing Infections in the Developing World, *Clin. Microbiol. Infect.*, 2010, **16**, 1062–1069.
- 74 C. M. Morel, Neglected Diseases: Under-funded Research and Inadequate Health Interventions, *EMBO Rep.*, 2003, **4**, S35–S38.
- 75 D. J. Weiss, T. C. D. Lucas, M. Nguyen, A. K. Nandi, D. Bisanzio, K. E. Battle, E. Cameron, K. A. Twohig, D. A. Pfeffer, J. A. Rozier, H. S. Gibson, P. C. Rao, D. Casey, A. Bertozzi-Villa, E. L. Collins, U. Dalrymple, N. Gray, J. R. Harris, R. E. Howes, S. Y. Kang, S. H. Keddie, D. May, S. Rumisha, M. P. Thorn, R. Barber, N. Fullman, C. K. Huynh, X. Kulikoff, M. J. Kutz, A. D. Lopez, A. H. Mokdad, M. Naghavi, G. Nguyen, K. A. Shackelford, T. Vos, H. Wang, D. L. Smith, S. S. Lim, C. J. L. Murray, S. Bhatt, S. I. Hay and P. W. Gething, Mapping the Global Prevalence, Incidence, and Mortality of Plasmodium Falciparum, 2000–17: A Spatial and Temporal Modelling Study, *Lancet*, 2019, **394**(10195), 322–331.
- 76 World Health Organization, Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000–2010, 2010.
- 77 A. M. Dondorp, F. Nosten, P. Yi, D. Das, A. P. Phyto, J. Tarning, K. M. Lwin, F. Ariey, W. Hanpithakpong, S. J. Lee, P. Ringwald, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S. S. An, S. Yeung, P. Singhasivanon, N. P. J. Day, N. Lindegardh, D. Socheat and N. J. White, Artemisinin Resistance in Plasmodium Falciparum Malaria, *N. Engl. J. Med.*, 2009, **361**(5), 455–467.
- 78 R. M. Fairhurst and A. M. Dondorp, Artemisinin-Resistant Plasmodium Falciparum Malaria, *Microbiol. Spectrum*, 2016, **4**(3), DOI: [10.1128/microbiolspec.EI10-0013-2016](https://doi.org/10.1128/microbiolspec.EI10-0013-2016).
- 79 S. D. Otienoburu, I. Suay, S. Garcia, N. V. Thomas, S. Srisutham, A. Björkman and G. S. Humphreys, An Online Mapping Database of Molecular Markers of Drug Resistance in Plasmodium Falciparum: The ACT Partner Drug Molecular Surveyor, *Malar. J.*, 2019, **18**(1), 12–21.
- 80 D. Shahinas, R. Lau, K. Khairnar, D. Hancock and D. R. Pillai, Artesunate Misuse and Plasmodium Falciparum Malaria in Traveler Returning from Africa, *Emerging Infect. Dis.*, 2010, **16**(10), 1608–1610.
- 81 A. A. A. Elmannan, K. A. Elmardi, Y. A. Idris, J. M. Spector, N. A. Ali and E. M. Malik, Anti-Malarial Prescribing Practices in Sudan Eight Years after Introduction of Artemisinin-Based Combination Therapies and Implications for Development of Drug Resistance, *BMC Pharmacol. Toxicol.*, 2015, **360**(5), 491–499 2015 16:1.
- 82 World Health Organization, *Guidelines for the Treatment of Malaria*, World Health Organization, 2nd edn, 2010.
- 83 J. D. Njau, C. A. Goodman, S. P. Kachur, J. Mulligan, J. S. Munkondya, N. Mchomvu, S. Abdulla, P. Bloland and A. Mills, The Costs of Introducing Artemisinin-Based Combination Therapy: Evidence from District-Wide Implementation in Rural Tanzania, *Malar. J.*, 2008, **7**(1), 4–17.
- 84 P. Olliaro, W. R. J. Taylor, J. Rigal, J. Mulligan, J. S. Munkondya, N. Mchomvu, S. Abdulla, P. Bloland and A. Mills, Controlling Malaria: Challenges and Solutions, *Trop. Med. Int. Health*, 2001, **6**(11), 922–927.
- 85 N. J. White, Antimalarial Drug Resistance, *J. Clin. Invest.*, 2004, **113**(8), 1084–1092.
- 86 I. J. Ezennia, S. O. Nduka and O. I. Ekwunife, Cost Benefit Analysis of Malaria Rapid Diagnostic Test: The Perspective of Nigerian Community Pharmacists, *Malar. J.*, 2017, **16**(1), 7–16.
- 87 UNICEF, Malaria Rapid Diagnostic Tests Market & Supply Update; 2016.
- 88 D. J. Weiss, T. C. D. Lucas, M. Nguyen, A. K. Nandi, D. Bisanzio, K. E. Battle, E. Cameron, K. A. Twohig, D. A. Pfeffer, J. A. Rozier, H. S. Gibson, P. C. Rao, D. Casey, A. Bertozzi-Villa, E. L. Collins, U. Dalrymple, N. Gray, J. R. Harris, R. E. Howes, S. Y. Kang, S. H. Keddie, D. May, S. Rumisha, M. P. Thorn, R. Barber, N. Fullman, C. K. Huynh, X. Kulikoff, M. J. Kutz, A. D. Lopez, A. H. Mokdad, M. Naghavi, G. Nguyen, K. A. Shackelford, T. Vos, H. Wang, D. L. Smith, S. S. Lim, C. J. L. Murray, S. Bhatt, S. I. Hay and P. W. Gething, Mapping the Global Prevalence, Incidence, and Mortality of Plasmodium Falciparum, 2000–17: A Spatial and Temporal Modelling Study, *Lancet*, 2019, **394**(10195), 322–331.
- 89 S. I. Hay and R. W. Snow, The Malaria Atlas Project: Developing Global Maps of Malaria Risk, *PLoS Med.*, 2006, **3**(12), e473.
- 90 S. I. Hay and R. W. Snow, The Malaria Atlas Project: Developing Global Maps of Malaria Risk, *PLoS Med.*, 2006, **3**(12), e473.
- 91 World Health Organization, How To Use a Rapid Diagnostic Test (RDT), 2008.
- 92 E. P. Rock, K. Marsh, A. J. Saul, T. E. Wellems, D. W. Taylor, W. L. Maloy and R. J. Howard, Comparative Analysis of the Plasmodium Falciparum Histidine-Rich Proteins HRP-I, HRP-II and HRP-III in Malaria Parasites of Diverse Origin, *Parasitology*, 1987, **95**(Pt 2), 209–227.
- 93 A. Moody, Rapid Diagnostic Tests for Malaria Parasites, *Clin. Microbiol. Rev.*, 2002, **15**(1), 66–78.
- 94 B. E. Barber, M. J. Grigg, T. William, T. W. Yeo and N. M. Anstey, The Treatment of Plasmodium Knowlesi Malaria, *Trends Parasitol.*, 2017, **33**(3), 242–253.
- 95 J. Field; P. Shute and A. Sandosham, The Microscopic Diagnosis of Human Malaria, Kuala Lumpur, 1956.
- 96 M. S. Cordray and R. R. Richards-Kortum, Review: Emerging Nucleic Acid-Based Tests for Point-of-Care Detection of Malaria, *Am. J. Trop. Med. Hyg.*, 2012, **87**(2), 223–230.
- 97 R. E. Coleman, N. Maneechai, N. Rachaphaew, C. Kumpitak, R. S. Miller, V. Soyseng, K. Thimasarn and J. Sattabongkot, Comparison of Field and Expert Laboratory Microscopy for Active Surveillance for Asymptomatic Plasmodium Falciparum and Plasmodium Vivax in Western Thailand, *Am. J. Trop. Med. Hyg.*, 2002, **67**, 141–144.
- 98 D. Lazer, M. A. Baum, A. Quintana, J. Druckman, J. Della and M. Simonson, The State Of The Nation: A 50-State Covid-19 Survey – Report #8: Failing the Test: Waiting Times for COVID Diagnostic Tests Across The U.S., 2020.



- 99 P. Raftery, O. Condell, C. Wasunna, J. Kpaka, R. Zwizwai, M. Nuha, M. Fallah, M. Freeman, V. Harris, M. Miller, A. Baller, M. Massaquoi, V. Katawera, J. Saindon, P. Bemah, E. Hamblion, E. Castle, D. Williams, A. Gasasira and T. Nyenswah, Establishing Ebola Virus Disease (EVD) Diagnostics Using GeneXpert Technology at a Mobile Laboratory in Liberia: Impact on Outbreak Response, Case Management and Laboratory Systems Strengthening, *PLoS Neglected Trop. Dis.*, 2018, **12**(1), e0006135.
- 100 J. C. Phan, J. Pettitt, J. S. George, L. S. Fakoli, F. M. Taweh, S. L. Bateman, R. S. Bennett, S. L. Norris, D. A. Spinnler, G. Pimentel, P. K. Sahr, F. K. Bolay and R. J. Schoepp, Lateral Flow Immunoassays for Ebola Virus Disease Detection in Liberia, *J. Infect. Dis.*, 2016, **214**(suppl 3), S222–S228.
- 101 A. Niemz, T. M. Ferguson and D. S. Boyle, Point-of-Care Nucleic Acid Testing for Infectious Diseases, *Trends Biotechnol.*, 2011, **29**(5), 240–250.
- 102 Y. Cao, L. Wang, L. Duan, J. Li, J. Ma, S. Xie, L. Shi and H. Li, Development of a Real-Time Fluorescence Loop-Mediated Isothermal Amplification Assay for Rapid and Quantitative Detection of *Ustilago Maydis*, *Sci. Rep.*, 2017, **7**(1), 13394.
- 103 G.-S. Park, K. Ku, S.-H. Baek, S.-J. Kim, S. I. Kim, B.-T. Kim and J.-S. Maeng, Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), *J. Mol. Diagn.*, 2020, **22**(6), 729–735.
- 104 J. C. Patel, N. W. Lucchi, P. Srivastava, J. T. Lin, R. Sugaram, S. Aruncharus, P. K. Bharti, M. M. Shukla, K. Congpuong, W. Satimai, N. Singh, V. Udhayakumar and S. R. Meshnick, Field Evaluation of a Real-Time Fluorescence Loop-Mediated Isothermal Amplification Assay, RealAmp, for the Diagnosis of Malaria in Thailand and India, *J. Infect. Dis.*, 2014, **210**(8), 1180–1187.
- 105 C. Aerts, M. Vink, S. J. Pashtoon, S. Nahzat, A. Picado, I. Cruz and E. Sicuri, Cost Effectiveness of New Diagnostic Tools for Cutaneous Leishmaniasis in Afghanistan, *Appl. Health Econ. Health Policy*, 2019, **17**(2), 213–230.
- 106 W. M. Stauffer, C. P. Cartwright, D. A. Olson, B. A. Juni, C. M. Taylor, S. H. Bowers, K. L. Hanson, J. E. Rosenblatt and D. R. Boulware, Diagnostic Performance of Rapid Diagnostic Tests versus Blood Smears for Malaria in US Clinical Practice, *Clin. Infect. Dis.*, 2009, **49**(6), 908–913.
- 107 M. Hawkes, J. P. Katsuva and C. K. Masumbuko, Use and Limitations of Malaria Rapid Diagnostic Testing by Community Health Workers in War-Torn Democratic Republic of Congo, *Malar. J.*, 2009, **8**(1), 308.
- 108 P. Jorgensen, L. Chanthap, A. Rebueno, R. Tsuyuoka and D. Bell, Malaria Rapid Diagnostic Tests in Tropical Climates: The Need for a Cool Chain, *Am. J. Trop. Med. Hyg.*, 2006, **74**(5), 750–754.
- 109 X. Mao, Y. Ma, A. Zhang, L. Zhang, L. Zeng and G. Liu, Disposable Nucleic Acid Biosensors Based on Gold Nanoparticle Probes and Lateral Flow Strip, *Anal. Chem.*, 2009, **81**(4), 1660–1668.
- 110 P. Damborský, K. M. Koczula, A. Gallotta and J. Katrlík, Lectin-Based Lateral Flow Assay: Proof-of-Concept, *Analyst*, 2016, **141**(23), 6444–6448.
- 111 R. Bertozzi C and L. L. Kiessling, Chemical Glycobiology, *Science*, 2001, **291**(5512), 2357–2364.
- 112 R. Apweiler, H. Hermjakob and N. Sharon, On the Frequency of Protein Glycosylation, as Deduced from Analysis of the SWISS-PROT Database, *Biochim. Biophys. Acta, Gen. Subj.*, 1999, **1473**(1), 4–8.
- 113 R. A. Flynn, K. Pedram, S. A. Malaker, P. J. Batista, B. A. H. Smith, A. G. Johnson, B. M. George, K. Majzoub, P. W. Villalta, J. E. Carette and C. R. Bertozzi, Small RNAs Are Modified with N-Glycans and Displayed on the Surface of Living Cells, *Cell*, 2021, **184**(12), 3109–3124.e22.
- 114 S. Dedola, M. D. Rugen, R. J. Young and R. A. Field, Revisiting the Language of Glycoscience: Readers, Writers and Erasers in Carbohydrate Biochemistry, *ChemBioChem*, 2020, **21**(3), 423–427.
- 115 R. S. Haltiwanger, Regulation of Signal Transduction Pathways in Development by Glycosylation, *Curr. Opin. Struct. Biol.*, 2002, 593–598.
- 116 J. J. Bustamante, L. Gonzalez, C. A. Carroll, S. T. Weintraub, R. M. Aguilar, J. Muñoz, A. O. Martinez and L. S. Haro, O-Glycosylated 24 KDa Human Growth Hormone Has a Mucin-like Biantennary Disialylated Tetrasaccharide Attached at Thr-60, *Proteomics*, 2009, **9**(13), 3474–3488.
- 117 A. Varki, R. Kannagi and B. P. Toole, *Glycosylation Changes in Cancer*, Cold Spring Harbor Laboratory Press, 2009.
- 118 D. Shental-Bechor and Y. Levy, Folding of Glycoproteins: Toward Understanding the Biophysics of the Glycosylation Code, *Curr. Opin. Struct. Biol.*, 2009, **19**(5), 524–533.
- 119 A. Helenius and M. Aebi, Roles of N-Linked Glycans in the Endoplasmic Reticulum, *Annu. Rev. Biochem.*, 2004, **73**(1), 1019–1049.
- 120 J. D. Marth and P. K. Grewal, Mammalian Glycosylation in Immunity, *Nat. Rev. Immunol.*, 2008, **8**(11), 874–887.
- 121 O. Yilmaz, B. Afsar, A. Ortiz and M. Kanbay, The Role of Endothelial Glycocalyx in Health and Disease, *Clin. Kidney J.*, 2019, **12**(5), 611–619.
- 122 Y. Xiong, Y. Chen, L. Ding, X. Liu and H. Ju, Fluorescent Visual Quantitation of Cell-Secreted Sialoglycoconjugates by Chemoselective Recognition and Hybridization Chain Reaction, *Analyst*, 2019, **144**(15), 4545–4551.
- 123 P. M. Chaudhary, R. V. Murthy, R. Yadav and R. Kikkeri, A Rationally Designed Peptidomimetic Biosensor for Sialic Acid on Cell Surfaces, *Chem. Commun.*, 2015, **51**(38), 8112–8115.
- 124 J. S. Long, B. Mistry, S. M. Haslam and W. S. Barclay, Host and Viral Determinants of Influenza A Virus Species Specificity, *Nat. Rev. Microbiol.*, 2019, **17**(2), 67–81.
- 125 A. Mostafa, E. Abdelwhab, T. Mettenleiter and S. Pleschka, Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview, *Viruses*, 2018, **10**(9), 497.
- 126 N. H. Tolia, E. J. Enemark, B. K. L. Sim and L. Joshua-Tor, Structural Basis for the EBA-175 Erythrocyte Invasion Pathway of the Malaria Parasite *Plasmodium Falciparum*, *Cell*, 2005, **122**(2), 183–193.



- 127 B. M. van den Berg, M. Nieuwdorp, E. Stroes and H. Vink, Endothelial Luminal Glycocalyx: Protective Barrier between Endothelial Cells and Flowing Blood, in *Endothelial Biomedicine*, ed. W. C. Aird, Cambridge University Press, Cambridge, 2007, pp. 689–695.
- 128 J. C. Manning, A. Romero, F. A. Habermann, G. García Caballero, H. Kaltner and H.-J. Gabius, Lectins: A Primer for Histochemists and Cell Biologists, *Histochem. Cell Biol.*, 2017, **147**(2), 199–222.
- 129 H. Ghazarian, B. Idoni and S. B. Oppenheimer, A Glycobiology Review: Carbohydrates, Lectins and Implications in Cancer Therapeutics, *Acta Histochem.*, 2011, **113**(3), 236–247.
- 130 A. A. Lindberg, J. E. Brown, N. Strömberg, M. Westling-Ryd, J. E. Schultz and K. A. Karlsson, Identification of the Carbohydrate Receptor for Shiga Toxin Produced by *Shigella Dysenteriae* Type 1, *J. Biol. Chem.*, 1987, **262**(4), 1779–1785.
- 131 R. L. Richards, J. Moss, C. R. Alving, P. H. Fishman and R. O. Brady, Cholera toxin (Cholera toxin): A bacterial lectin, *Proc. Natl. Acad. Sci. U. S. A.*, 1979, **76**(4), 1673–1676.
- 132 S. S. Li, C. H. Wei, J.-Y. Lin and T.-C. Tung, Amino-Terminal Sequences of the Anti-Tumor Lectin Ricin A- and B-Chains, *Biochem. Biophys. Res. Commun.*, 1975, **65**(4), 1191–1195.
- 133 M. A. Sartim and S. V. Sampaio, Snake Venom Galactoside-Binding Lectins: A Structural and Functional Overview, *J. Venomous Anim. Toxins Incl. Trop. Dis.*, 2015, **21**, 35.
- 134 W.-R. Liao, J.-Y. Lin, W.-Y. Shieh, W.-L. Jeng and R. Huang, Antibiotic Activity of Lectins from Marine Algae against Marine Vibrios, *J. Ind. Microbiol. Biotechnol.*, 2003, **30**(7), 433–439.
- 135 R. Jelinek and S. Kolusheva, Carbohydrate Biosensors, *Chem. Rev.*, 2004, **104**(12), 5987–6015.
- 136 S. Cunningham, J. Q. Gerlach, M. Kane and L. Joshi, Glyco-Biosensors: Recent Advances and Applications for the Detection of Free and Bound Carbohydrates, *Analyst*, 2010, **135**(10), 2471–2480.
- 137 A. Bernardi, J. Jiménez-Barbero, A. Casnati, C. De Castro, T. Darbre, F. Fieschi, J. Finne, H. Funken, K.-E. Jaeger, M. Lahmann, T. K. Lindhorst, M. Marradi, P. Messner, A. Molinaro, P. V. Murphy, C. Nativi, S. Oscarson, S. Penadés, F. Peri, R. J. Pieters, O. Renaudet, J.-L. Reymond, B. Richichi, J. Rojo, F. Sansone, C. Schäffer, W. B. Turnbull, T. Velasco-Torrijos, S. Vidal, S. Vincent, T. Wennekes, H. Zuillhof and A. Imberty, Multivalent Glycoconjugates as Anti-Pathogenic Agents, *Chem. Soc. Rev.*, 2013, **42**(11), 4709–4727.
- 138 N. Sharon, Carbohydrates as Future Anti-Adhesion Drugs for Infectious Diseases, *Biochim. Biophys. Acta, Gen. Subj.*, 2006, **1760**(4), 527–537.
- 139 M. Marradi, F. Chiodo, I. García, S. Penadés, G. M. Whitesides, D. Y. Lee, H. Shin, R. J. Pieters, J. M. Fuente, S.-H. de la; Nishimura, P. Arosio, A. Lascialfari, D. Gatteschi and C. Sangregorio, Glyconanoparticles as Multifunctional and Multimodal Carbohydrate Systems, *Chem. Soc. Rev.*, 2013, **42**(11), 4728.
- 140 N. C. Reichardt, M. Martín-Lomas, S. Penadés, M. Andersson, A. Thran, R. Proksa, Z. A. Fayad, D. P. Cormode, C. Y. Wu, C. H. Wong, M. L. H. Green, K. Kostarelos, B. G. Davis and S. P. Vincent, Glyconanotechnology, *Chem. Soc. Rev.*, 2013, **42**(10), 4358–4376.
- 141 L. T. Lui, X. Xue, C. Sui, A. Brown, D. I. Pritchard, N. Halliday, K. Winzer, S. M. Howdle, F. Fernandez-Trillo, N. Krasnogor and C. Alexander, Bacteria Clustering by Polymers Induces the Expression of Quorum-Sensing-Controlled Phenotypes, *Nat. Chem.*, 2013, **5**(12), 1058–1065.
- 142 D. Chang and J. Zaia, Why Glycosylation Matters in Building a Better Flu Vaccine, *Mol. Cell. Proteomics*, 2019, **18**(12), 2348–2358.
- 143 T. Tokatlian, B. J. Read, C. A. Jones, D. W. Kulp, S. Menis, J. Y. H. Chang, J. M. Steichen, S. Kumari, J. D. Allen, E. L. Dane, A. Liguori, M. Sangesland, D. Lingwood, M. Crispin, W. R. Schief and D. J. Irvine, Innate Immune Recognition of Glycans Targets HIV Nanoparticle Immunogens to Germinal Centers, *Science*, 2019, **363**(6427), 649–654.
- 144 G.-J. Boons, Strategies in Oligosaccharide Synthesis, *Tetrahedron*, 1996, **52**(4), 1095–1121.
- 145 B. Lepenies, J. Yin and P. H. Seeberger, Applications of Synthetic Carbohydrates to Chemical Biology, *Curr. Opin. Chem. Biol.*, 2010, **14**(3), 404–411.
- 146 O. J. Plante, E. R. Palmacci and P. H. Seeberger, Automated Solid-Phase Synthesis of Oligosaccharides, *Science*, 2001, **291**(5508), 1523–1527.
- 147 A. A. Joseph, A. Pardo-Vargas and P. H. Seeberger, Total Synthesis of Polysaccharides by Automated Glycan Assembly, *J. Am. Chem. Soc.*, 2020, **142**(19), 8561–8564.
- 148 M. Guberman and P. H. Seeberger, Automated Glycan Assembly: A Perspective, *J. Am. Chem. Soc.*, 2019, **141**(14), 5581–5592.
- 149 S. Flitsch, Chemical and Enzymatic Synthesis of Glycopolymers, *Curr. Opin. Chem. Biol.*, 2000, **4**(6), 619–625.
- 150 T. Li, L. Liu, N. Wei, J. Y. Yang, D. G. Chapla, K. W. Moremen and G. J. Boons, An Automated Platform for the Enzyme-Mediated Assembly of Complex Oligosaccharides, *Nat. Chem.*, 2019, **11**(3), 229–236.
- 151 S. J. Richards, T. Keenan, J. B. Vendeville, D. E. Wheatley, H. Chidwick, D. Budhadev, C. E. Council, C. S. Webster, H. Ledru, A. N. Baker, M. Walker, M. C. Galan, B. Linclau, M. A. Fascione and M. I. Gibson, Introducing Affinity and Selectivity into Galectin-Targeting Nanoparticles with Fluorinated Glycan Ligands, *Chem. Sci.*, 2021, **12**(3), 905–910.
- 152 J. J. Lundquist and E. J. Toone, The Cluster Glycoside Effect, *Chem. Rev.*, 2002, **102**(2), 555–578.
- 153 Y. C. Lee and R. T. Lee, Carbohydrate-Protein Interactions: Basis of Glycobiology, *Acc. Chem. Res.*, 1995, **28**(8), 321–327.
- 154 R. J. Pieters, Maximising Multivalency Effects in Protein–Carbohydrate Interactions, *Org. Biomol. Chem.*, 2009, **7**(10), 2013–2025.
- 155 T. R. Branson, T. E. McAllister, J. Garcia-Hartjes, M. A. Fascione, J. F. Ross, S. L. Warriner, T. Wennekes,



- H. Zuillhof and W. B. Turnbull, A Protein-Based Pentavalent Inhibitor of the Cholera Toxin B-Subunit, *Angew. Chem., Int. Ed.*, 2014, **53**(32), 8323–8327.
- 156 S.-J. Richards and M. I. Gibson, Toward Glycomaterials with Selectivity as Well as Affinity, *JACS Au*, 2021, **1**(12), 2089–2099.
- 157 Z. Wang, Z. S. Chinoy, S. G. Ambre, W. Peng, R. McBride, R. P. de Vries, J. Glushka, J. C. Paulson and G.-J. Boons, A General Strategy for the Chemoenzymatic Synthesis of Asymmetrically Branched N-Glycans, *Science*, 2013, **341**(6144), 379–383.
- 158 S. André, M. Lahmann, H.-J. Gabius and S. Oscarson, Glycocluster Design for Improved Avidity and Selectivity in Blocking Human Lectin/Plant Toxin Binding to Glycoproteins and Cells, *Mol. Pharmaceutics*, 2010, **7**(6), 2270–2279.
- 159 S. Wang, L. Dupin, M. Noël, C. J. Carroux, L. Renaud, T. Géhin, A. Meyer, E. Souteyrand, J.-J. Vasseur, G. Vergoten, Y. Chevolut, F. Morvan and S. Vidal, Toward the Rational Design of Galactosylated Glycoclusters That Target *Pseudomonas Aeruginosa* Lectin A (LecA): Influence of Linker Arms That Lead to Low-Nanomolar Multivalent Ligands, *Chem. – Eur. J.*, 2016, **22**(33), 11785–11794.
- 160 T. K. Lindhorst, C. Kieburg and U. Krallmann-Wenzel, Inhibition of the Type 1 Fimbriae-Mediated Adhesion of *Escherichia Coli* to Erythrocytes by Multiantennary α -Mannosyl Clusters: The Effect of Multivalency, *Glycoconjugate J.*, 1998, **15**, 605–613.
- 161 I. S. MacPherson, J. S. Temme, S. Habeshian, K. Felczak, K. Pankiewicz, L. Hedstrom and I. J. Krauss, Multivalent Glycocluster Design through Directed Evolution, *Angew. Chem., Int. Ed.*, 2011, **50**(47), 11238–11242.
- 162 N. Jayaraman, S. A. Nepogodiev and J. F. Stoddart, Synthetic Carbohydrate-Containing Dendrimers, *Chem. – Eur. J.*, 1997, **3**(8), 1193–1199.
- 163 W. B. Turnbull, S. A. Kalovidouris and J. F. Stoddart, Large Oligosaccharide-Based Glycodendrimers Synthetic Carbohydrate Dendrimers, *Chem. – Eur. J.*, 2002, **8**(13), 2988–3000.
- 164 E. K. Woller and M. J. Cloninger, The Lectin-Binding Properties of Six Generations of Mannose-Functionalized Dendrimers, *Org. Lett.*, 2002, **4**(1), 7–10.
- 165 S. Mignani, J. Rodrigues, H. Tomas, R. Roy, X. Shi and J.-P. Majoral, Bench-to-Bedside Translation of Dendrimers: Reality or Utopia? A Concise Analysis, *Adv. Drug Delivery Rev.*, 2018, **136–137**, 73–81.
- 166 S. Zhang, Q. Xiao, S. E. Sherman, A. Muncan, A. D. M. Ramos Vicente, Z. Wang, D. A. Hammer, D. Williams, Y. Chen, D. J. Pochan, S. Vértessy, S. André, M. L. Klein, H. J. Gabius and V. Percec, Glycodendrimersomes from Sequence-Defined Janus Glycodendrimers Reveal High Activity and Sensor Capacity for the Agglutination by Natural Variants of Human Lectins, *J. Am. Chem. Soc.*, 2015, **137**(41), 13334–13344.
- 167 S. G. Spain, M. I. Gibson and N. R. Cameron, Recent Advances in the Synthesis of Well-Defined Glycopolymers, *J. Polym. Sci., Part A: Polym. Chem.*, 2007, **45**(11), 2059–2072.
- 168 C. von der Ehe, C. Weber, M. Gottschaldt and U. S. Schubert, Immobilized Glycopolymers: Synthesis, Methods and Applications, *Prog. Polym. Sci.*, 2016, **57**, 64–102.
- 169 V. Vázquez-Dorbatt and H. D. Maynard, Biotinylated Glycopolymers Synthesized by Atom Transfer Radical Polymerization, *Biomacromolecules*, 2006, **7**(8), 2297–2302.
- 170 A. B. Lowe, B. S. Sumerlin and C. L. McCormick, The Direct Polymerization of 2-Methacryloxyethyl Glucoside via Aqueous Reversible Addition-Fragmentation Chain Transfer (RAFT) Polymerization, *Polymer*, 2003, **44**(22), 6761–6765.
- 171 L. E. Strong and L. L. Kiessling, A General Synthetic Route to Defined, Biologically Active Multivalent Arrays, *J. Am. Chem. Soc.*, 1999, **121**(26), 6193–6196.
- 172 K. Ohno, Y. Tsujii, T. Miyamoto, T. Fukuda, M. Goto, K. Kobayashi and T. Akaike, Synthesis of a Well-Defined Glycopolymer by Nitroxide-Controlled Free Radical Polymerization, *Macromolecules*, 1998, **31**(4), 1064–1069.
- 173 M. Mammen, G. Dahmann and G. M. Whitesides, Effective Inhibitors of Hemagglutination by Influenza Virus Synthesized from Polymers Having Active Ester Groups. Insight into Mechanism of Inhibition, *J. Med. Chem.*, 1995, **38**(21), 4179–4190.
- 174 G. B. Sigal, M. Mammen, G. Dahmann and G. M. Whitesides, Polyacrylamides Bearing Pendant α -Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza Virus: The Strong Inhibition Reflects Enhanced Binding through Cooperative Polyvalent Interactions, *J. Am. Chem. Soc.*, 1996, **118**(16), 3789–3800.
- 175 X. Xue, G. Pasparakis, N. Halliday, K. Winzer, S. M. Howdle, C. J. Cramphorn, N. R. Cameron, P. M. Gardner, B. G. Davis, F. Fernández-Trillo, C. Alexander, F. Fernández-Trillo and C. Alexander, Synthetic Polymers for Simultaneous Bacterial Sequestration and Quorum Sense Interference, *Angew. Chem., Int. Ed.*, 2011, **50**(42), 9852–9856.
- 176 R. J. Pieters, Intervention with Bacterial Adhesion by Multivalent Carbohydrates, *Med. Res. Rev.*, 2007, **27**(6), 796–816.
- 177 A. G. Kruger, S. D. Brucks, T. Yan, G. Cárcarmo-Oyarce, Y. Wei, D. H. Wen, D. R. Carvalho, M. J. A. Hore, K. Ribbeck, R. R. Schrock and L. L. Kiessling, Stereochemical Control Yields Mucin Mimetic Polymers, *ACS Cent. Sci.*, 2021, **7**(4), 624–630.
- 178 M. Nagao, M. Kichize, Y. Hoshino and Y. Miura, Influence of Monomer Structures for Polymeric Multivalent Ligands: Consideration of the Molecular Mobility of Glycopolymers, *Biomacromolecules*, 2021, **22**(7), 3119–3127.
- 179 L. E. Wilkins, N. Badi, F. Du Prez and M. I. Gibson, Double-Modified Glycopolymers from Thiolactones to Modulate Lectin Selectivity and Affinity, *ACS Macro Lett.*, 2018, **7**(12), 1498–1502.
- 180 M. W. Jones, L. Otten, S.-J. Richards, R. Lowery, D. J. Phillips, D. M. Haddleton and M. I. Gibson, Glycopolymers with Secondary Binding Motifs Mimic Glycan Branching and Display Bacterial Lectin Selectivity in Addition to Affinity, *Chem. Sci.*, 2014, **5**(4), 1611–1616.



- 181 S.-J. Richards, M. W. Jones, M. Hunaban, D. M. Haddleton and M. I. Gibson, Probing Bacterial-Toxin Inhibition with Synthetic Glycopolymers Prepared by Tandem Post-Polymerization Modification: Role of Linker Length and Carbohydrate Density, *Angew. Chem., Int. Ed.*, 2012, **51**(31), 7812–7816.
- 182 B. D. Polizzotti and K. L. Kiick, Effects of Polymer Structure on the Inhibition of Cholera Toxin by Linear Polypeptide-Based Glycopolymers, *Biomacromolecules*, 2006, **7**(2), 483–490.
- 183 H.-A. Tran, P. I. Kitov, E. Paszkiewicz, J. M. Sadowska and D. R. Bundle, Multifunctional Multivalency: A Focused Library of Polymeric Cholera Toxin Antagonists, *Org. Biomol. Chem.*, 2011, **9**(10), 3658–3671.
- 184 B. Martyn, C. I. Biggs and M. I. Gibson, Comparison of Systematically Functionalized Heterogeneous and Homogenous Glycopolymers as Toxin Inhibitors, *J. Polym. Sci., Part A: Polym. Chem.*, 2019, **57**(1), 40–47.
- 185 D. Ponader, P. Maffre, J. Aretz, D. Pussak, N. M. Ninnemann, S. Schmidt, P. H. Seeberger, C. Rademacher, G. U. Nienhaus and L. Hartmann, Carbohydrate-Lectin Recognition of Sequence-Defined Heteromultivalent Glycooligomers, *J. Am. Chem. Soc.*, 2014, **136**(5), 2008–2016.
- 186 C. S. Mahon, M. A. Fascione, C. Sakonsinsiri, T. E. McAllister, W. B. Turnbull and D. A. Fulton, Templating Carbohydrate-Functionalised Polymer-Scaffolded Dynamic Combinatorial Libraries with Lectins, *Org. Biomol. Chem.*, 2015, **13**(9), 2756–2761.
- 187 A. L. Parry, N. A. Clemson, J. Ellis, S. S. R. Bernhard, B. G. Davis and N. R. Cameron, “Multicopy Multivalent” Glycopolymer-Stabilized Gold Nanoparticles as Potential Synthetic Cancer Vaccines, *J. Am. Chem. Soc.*, 2013, **135**(25), 9362–9365.
- 188 Y. Qu, Y. Li, S. Liao, J. Sun, M. Li, D. Wang, C. Xia, Q. Luo, J. Hu, K. Luo, Q. Gong and B. Song, Linear and Core-Crosslinked Glycopolymer-Gadolinium Conjugates: Preparation and Their Behaviors as Nanoscale Magnetic Resonance Imaging Contrast Agents, *J. Biomed. Nanotechnol.*, 2019, **15**(8), 1637–1653.
- 189 Y. Wang, Y. Dai, Q. Luo, X. Wei, X. Xiao, H. Li, J. Hu, Q. Gong, J. Wu and K. Luo, Tumor Environment-Responsive Degradable Branched Glycopolymer Magnetic Resonance Imaging Contrast Agent and Its Tumor-Targeted Imaging, *J. Biomed. Nanotechnol.*, 2019, **15**(7), 1384–1400.
- 190 C. Cao, J. Zhao, M. Lu, C. J. Garvey and M. H. Stenzel, Correlation between Drug Loading Content and Biological Activity: The Complexity Demonstrated in Paclitaxel-Loaded Glycopolymer Micelle System, *Biomacromolecules*, 2019, **20**(4), 1545–1554.
- 191 J. Wu, J. Yuan, B. Ye, Y. Wu, Z. Xu, J. Chen and J. Chen, Dual-Responsive Core Crosslinking Glycopolymer-Drug Conjugates Nanoparticles for Precise Hepatocarcinoma Therapy, *Front. Pharmacol.*, 2018, **9**, 663.
- 192 R. S. Loka, E. T. Sletten, U. Barash, I. Vlodaysky and H. M. Nguyen, Specific Inhibition of Heparanase by a Glycopolymer with Well-Defined Sulfation Pattern Prevents Breast Cancer Metastasis in Mice, *ACS Appl. Mater. Interfaces*, 2019, **11**(1), 244–254.
- 193 M. L. Huang, R. A. A. Smith, G. W. Triegeer and K. Godula, Glycocalyx Remodeling with Proteoglycan Mimetics Promotes Neural Specification in Embryonic Stem Cells, *J. Am. Chem. Soc.*, 2014, **136**(30), 10565–10568.
- 194 M. Chikae, T. Fukuda, K. Kerman, K. Idegami, Y. Miura and E. Tamiya, Amyloid- β Detection with Saccharide Immobilized Gold Nanoparticle on Carbon Electrode, *Bioelectrochemistry*, 2008, **74**(1), 118–123.
- 195 C. K. Adokoh, S. Quan, M. Hitt, J. Darkwa, P. Kumar and R. Narain, Synthesis and Evaluation of Glycopolymeric Decorated Gold Nanoparticles Functionalized with Gold-Triphenyl Phosphine as Anti-Cancer Agents, *Biomacromolecules*, 2014, **15**(10), 3802–3810.
- 196 M. Ahmed, Z. Deng and R. Narain, Study of Transfection Efficiencies of Cationic Glyconanoparticles of Different Sizes in Human Cell Line, *ACS Appl. Mater. Interfaces*, 2009, **1**(9), 1980–1987.
- 197 Z. Wang, Z. S. Chinoy, S. G. Ambre, W. Peng, R. McBride, R. P. de Vries, J. Glushka, J. C. Paulson and G.-J. Boons, A General Strategy for the Chemoenzymatic Synthesis of Asymmetrically Branched N-Glycans, *Science*, 2013, **341**(6144), 379–383.
- 198 P. J. Hernando, S. Dedola, M. J. Marín and R. A. Field, Recent Developments in the Use of Glyconanoparticles and Related Quantum Dots for the Detection of Lectins, Viruses, Bacteria and Cancer Cells, *Front. Chem.*, 2021, **9**, 560.
- 199 A. Hucknall, S. Rangarajan and A. Chilkoti, In Pursuit of Zero: Polymer Brushes That Resist the Adsorption of Proteins, *Adv. Mater.*, 2009, **21**(23), 2441–2446.
- 200 J. O. Zoppe, N. C. Ataman, P. Mocny, J. Wang, J. Moraes and H. A. Klok, Surface-Initiated Controlled Radical Polymerization: State-of-the-Art, Opportunities, and Challenges in Surface and Interface Engineering with Polymer Brushes, *Chem. Rev.*, 2017, **117**(3), 1105–1318.
- 201 M. J. Marín, A. Rashid, M. Rejzek, S. A. Fairhurst, S. A. Wharton, S. R. Martin, J. W. McCauley, T. Wileman, R. A. Field and D. A. Russell, Glyconanoparticles for the Plasmonic Detection and Discrimination between Human and Avian Influenza Virus, *Org. Biomol. Chem.*, 2013, **11**(41), 7101.
- 202 Á. G. Barrientos, J. M. De la Fuente, T. C. Rojas, A. Fernández and S. Penadés, Gold Glyconanoparticles: Synthetic Polyvalent Ligands Mimicking Glycocalyx-like Surfaces as Tools for Glycobiological Studies, *Chem. – Eur. J.*, 2003, **9**(9), 1909–1921.
- 203 M. J. Hernáiz, J. M. De La Fuente, Á. G. Barrientos and S. Penadés, A Model System Mimicking Glycosphingolipid Clusters to Quantify Carbohydrate Self-Interactions by Surface Plasmon Resonance, *Angew. Chem., Int. Ed.*, 2002, **41**(9), 1554–1557.
- 204 A. B. Lowe, B. S. Sumerlin, M. S. Donovan and C. L. McCormick, Facile Preparation of Transition Metal Nanoparticles Stabilized by Well-Defined (Co)Polymers



- Synthesized via Aqueous Reversible Addition-Fragmentation Chain Transfer Polymerization, *J. Am. Chem. Soc.*, 2002, **124**(39), 11562–11563.
- 205 S. G. Spain, L. Albertin and N. R. Cameron, Facile in Situ Preparation of Biologically Active Multivalent Glyconanoparticles, *Chem. Commun.*, 2006, 4198–4200.
- 206 A. L. Parry, N. A. Clemson, J. Ellis, S. S. R. Bernhard, B. G. Davis and N. R. Cameron, “Multicopy Multivalent” Glycopolymer-Stabilized Gold Nanoparticles as Potential Synthetic Cancer Vaccines, *J. Am. Chem. Soc.*, 2013, **135**(25), 9362–9365.
- 207 G. Yilmaz, E. Guler, C. Geyik, B. Demir, M. Ozkan, D. Odaci Demirkol, S. Ozcelik, S. Timur and C. R. Becer, PH Responsive Glycopolymer Nanoparticles for Targeted Delivery of Anti-Cancer Drugs, *Mol. Syst. Des. Eng.*, 2018, **3**(1), 150–158.
- 208 F.-W. Shen, K.-C. Zhou, H. Cai, Y.-N. Zhang, Y.-L. Zheng and J. Quan, One-Pot Synthesis of Thermosensitive Glycopolymers Grafted Gold Nanoparticles and Their Lectin Recognition, *Colloids Surf., B*, 2019, **173**, 504–511.
- 209 K. Mizukami, H. Takakura, T. Matsunaga and H. Kitano, Binding of Ricinus Communis Agglutinin to a Galactose-Carrying Polymer Brush on a Colloidal Gold Monolayer, *Colloids Surf., B*, 2008, **66**(1), 110–118.
- 210 S. Nu, H. Bttcher, H. Wurm and M. L. Hallensleben, Gold Nanoparticles with Covalently Attached Polymer Chains, *Angew. Chem., Int. Ed.*, 2001, **40**(21), 4016–4018.
- 211 L. Wu, U. Glebe and A. Böker, Surface-Initiated Controlled Radical Polymerizations from Silica Nanoparticles, Gold Nanocrystals, and Bionanoparticles, *Polym. Chem.*, 2015, **6**(29), 5143–5184.
- 212 H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov and P. E. Bourne, The Protein Data Bank, *Nucleic Acids Res.*, 2000, **28**(1), 235–242.
- 213 L. R. Olsen, A. Dessen, D. Gupta, S. Sabesan, J. C. Sacchettini and C. F. Brewer, X-Ray Crystallographic Studies of Unique Cross-Linked Lattices between Four Isomeric Biantennary Oligosaccharides and Soybean Agglutinin, *Biochemistry*, 1997, **36**(49), 15073–15080.
- 214 K. D. Hardman and C. F. Ainsworth, Structure of Concanavalin A at 2.4-Ång Resolution, *Biochemistry*, 1972, **11**(26), 4910–4919.
- 215 R. G. Zhang, D. L. Scott, M. L. Westbrook, S. Nance, B. D. Spangler, G. G. Shipley and E. M. Westbrook, The Three-Dimensional Crystal Structure of Cholera Toxin, *J. Mol. Biol.*, 1995, **251**, 563–573.
- 216 D. Schwefel, C. Maierhofer, J. G. Beck, S. Seeberger, K. Diederichs, H. M. Moller, W. Welte and V. Wittmann, Structural Basis of Multivalent Binding to Wheat Germ Agglutinin, *J. Am. Chem. Soc.*, 2010, **132**, 8704–8719.
- 217 S. K. Natchiar, O. Srinivas, N. Mitra, A. Suroliya, N. Jayaraman and M. Vijayan, Structural Studies on Peanut Lectin Complexed with Disaccharides Involving Different Linkages: Further Insights into the Structure and Interactions of the Lectin, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2006, **62**, 1413–1421.
- 218 M. J. Marín, C. L. Schofield, R. A. Field and D. A. Russell, Glyconanoparticles for Colorimetric Bioassays, *Analyst*, 2015, **140**(1), 59–70.
- 219 C. A. Mirkin, R. L. Letsinger, R. C. Mucic and J. J. Storhoff, A DNA-Based Method for Rationally Assembling Nanoparticles into Macroscopic Materials, *Nature*, 1996, **382**(6592), 607–609.
- 220 J. L. Wang and G. M. Edelman, Binding and Functional Properties of Concanavalin A and Its Derivatives. II. A Proteolytic Product with Saccharide Binding Activity, *J. Biol. Chem.*, 1978, **253**(9), 3008–3015.
- 221 H. de Boeck, H. Lis, H. van Tilbeurgh, N. Sharon and F. G. Loontjens, Binding of Simple Carbohydrates and Some of Their Chromophoric Derivatives to Soybean Agglutinin as Followed by Titrimetric Procedures and Stopped Flow Kinetics, *J. Biol. Chem.*, 1984, **259**(11), 7067–7074.
- 222 M. Toyoshima, K. Ooya, Y. Miura and K. Kobayashi, Preparation and Biological Properties of Saccharide-Modified Gold Nanoparticles, *J. Jpn. Soc. Powder Powder Metall.*, 2007, **54**(12), 843–848.
- 223 C. L. Schofield, B. Mukhopadhyay, S. M. Hardy, M. B. McDonnell, R. A. Field and D. A. Russell, Colorimetric Detection of Ricinus Communis Agglutinin 120 Using Optimally Presented Carbohydrate-Stabilised Gold Nanoparticles, *Analyst*, 2008, **133**(5), 626–634.
- 224 X.-L. Hu, H.-Y. Jin, X.-P. He, T. D. James, G.-R. Chen and Y.-T. Long, Colorimetric and Plasmonic Detection of Lectins Using Core-Shell Gold Glyconanoparticles Prepared by Copper-Free Click Chemistry, *ACS Appl. Mater. Interfaces*, 2015, **7**(3), 1874–1878.
- 225 X.-P. He, Y.-L. Zeng, Y. Zang, J. Li, R. A. Field and G.-R. Chen, Carbohydrate CuAAC Click Chemistry for Therapy and Diagnosis, *Carbohydr. Res.*, 2016, **429**, 1–22.
- 226 C. L. Schofield, R. A. Field and D. A. Russell, Glyconanoparticles for the Colorimetric Detection of Cholera Toxin, *Anal. Chem.*, 2007, **79**(4), 1356–1361.
- 227 S.-J. Richards and M. I. Gibson, Optimization of the Polymer Coating for Glycosylated Gold Nanoparticle Biosensors to Ensure Stability and Rapid Optical Readouts, *ACS Macro Lett.*, 2014, **3**(10), 1004–1008.
- 228 S. Won, S.-J. Richards, M. Walker and M. I. Gibson, Externally Controllable Glycan Presentation on Nanoparticle Surfaces to Modulate Lectin Recognition, *Nanoscale Horiz.*, 2017, **3**(2), 1593–1608.
- 229 M. Toyoshima and Y. Miura, Preparation of Glycopolymer-Substituted Gold Nanoparticles and Their Molecular Recognition, *J. Polym. Sci., Part A: Polym. Chem.*, 2009, **47**(5), 1412–1421.
- 230 S.-J. Richards, E. C. Fullam, G. S. Besra and M. I. Gibson, Discrimination between Bacterial Phenotypes Using Glyconanoparticles and the Impact of Polymer Coating on Detection Readouts, *J. Mater. Chem. B*, 2014, **2**(11), 1490–1498.
- 231 I. García, J. Mosquera, J. Plou and L. M. Liz-Marzán, Plasmonic Detection of Carbohydrate-Mediated Biological Events, *Adv. Opt. Mater.*, 2018, **6**(23), 1800680.



- 232 D. Craig, J. Simpson, K. Faulds and D. Graham, Formation of SERS Active Nanoparticle Assemblies via Specific Carbohydrate-Protein Interactions, *Chem. Commun.*, 2013, **49**(1), 30–32.
- 233 J. Langer, I. García and L. M. Liz-Marzán, Real-Time Dynamic SERS Detection of Galectin Using Glycan-Decorated Gold Nanoparticles, *Faraday Discuss.*, 2017, **205**(0), 363–375.
- 234 M. Toyoshima, T. Oura, T. Fukuda, E. Matsumoto and Y. Miura, Biological Specific Recognition of Glycopolymer-Modified Interfaces by RAFT Living Radical Polymerization, *Polym. J.*, 2010, **42**(2), 172–178.
- 235 J. Ishii, M. Toyoshima, M. Chikae, Y. Takamura and Y. Miura, Preparation of Glycopolymer-Modified Gold Nanoparticles and a New Approach for a Lateral Flow Assay, *Bull. Chem. Soc. Jpn.*, 2011, **84**(5), 466–470.
- 236 M. Takara, M. Toyoshima, H. Seto, Y. Hoshino and Y. Miura, Polymer-Modified Gold Nanoparticles via RAFT Polymerization: A Detailed Study for a Biosensing Application, *Polym. Chem.*, 2014, **5**(3), 931–939.
- 237 N. Sze Jeong, C. I. Biggs, M. Walker and M. I. Gibson, Comparison of RAFT-Derived Poly(Vinylpyrrolidone) Verses Poly(Oligoethyleneglycol Methacrylate) for the Stabilization of Glycosylated Gold Nanoparticles, *J. Polym. Sci., Part A: Polym. Chem.*, 2017, **55**(7), 1200–1208.
- 238 P. G. Georgiou, A. N. Baker, S.-J. J. Richards, A. Laezza, M. Walker and M. I. Gibson, Tuning Aggregative versus Non-Aggregative Lectin Binding with Glycosylated Nanoparticles by the Nature of the Polymer Ligand, *J. Mater. Chem. B*, 2020, **8**(1), 136–145.
- 239 A. N. Baker, S. J. Richards, C. S. Guy, T. R. Congdon, M. Hasan, A. J. Zwetsloot, A. Gallo, J. R. Lewandowski, P. J. Stansfeld, A. Straube, M. Walker, S. Chessa, G. Pergolizzi, S. Dedola, R. A. Field and M. I. Gibson, The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device. ACS Central, *Science*, 2020, **6**(11), 2046–2052.
- 240 L. Nguyen, K. A. McCord, D. T. Bui, K. A. Bouwman, E. N. Kitova, D. Kumawat, G. C. Daskan, I. Tomris, L. Han, P. Chopra, T.-J. Yang, S. D. Willows, T. L. Lowary, L. J. West, S.-T. D. Hsu, S. M. Tompkins, G.-J. Boons, A. L. Mason, R. P. de Vries, M. S. Macauley and J. S. Klassen, Sialic Acid-Containing Glycolipids Mediate Binding and Viral Entry of SARS-CoV-2, *Nat. Chem. Biol.*, 2022, **18**, 81–90.
- 241 C. J. Buchanan, B. Gaunt, P. J. Harrison, Y. Yang, J. Liu, A. Khan, A. M. Giltrap, A. Le Bas, P. N. Ward, K. Gupta, M. Dumoux, T. K. Tan, L. Schimaski, S. Daga, N. Picchiotti, M. Baldassarri, E. Benetti, C. Fallerini, F. Fava, A. Giliberti, P. I. Koukos, M. J. Davy, A. Lakshminarayanan, X. Xue, G. Papadakis, L. P. Deimel, V. Casablancas-Antràs, T. D. W. Claridge, A. M. J. J. Bonvin, Q. J. Sattentau, S. Furini, M. Gori, J. Huo, R. J. Owens, C. Schaffitzel, I. Berger, A. Renieri, J. H. Naismith, A. J. Baldwin and B. G. Davis, Pathogen-Sugar Interactions Revealed by Universal Saturation Transfer Analysis, *Science*, 2022, DOI: [10.1126/science.abm3125](https://doi.org/10.1126/science.abm3125).
- 242 A. N. Baker, S.-J. Richards, S. Pandey, C. S. Guy, A. Ahmad, M. Hasan, C. I. Biggs, P. G. Georgiou, A. J. Zwetsloot, A. Straube, S. Dedola, R. A. Field, N. R. Anderson, M. Walker, D. Grammatopoulos and M. I. Gibson, Glycan-Based Flow-Through Device for the Detection of SARS-COV-2, *ACS Sens.*, 2021, **6**(10), 3696–3705.
- 243 A. N. Baker, A. R. Muguruza, S. Richards, P. G. Georgiou, S. Goetz, M. Walker, S. Dedola, R. A. Field and M. I. Gibson, Lateral Flow Glyco-Assays for the Rapid and Low-Cost Detection of Lectins – Polymeric Linkers and Particle Engineering Are Essential for Selectivity and Performance, *Adv. Healthcare Mater.*, 2022, **11**, 2101784.
- 244 A. N. Baker, T. R. Congdon, S.-J. Richards, P. G. Georgiou, M. Walker, S. Dedola, R. A. Field and M. I. Gibson, End-Functionalized Poly(Vinylpyrrolidone) for Ligand Display in Lateral Flow Device Test Lines, *ACS Polym. Au*, 2022, **2**(2), 69–79.
- 245 S. H. Kim, F. L. Kearns, M. A. Rosenfeld, L. Casalino, M. J. Papanikolas, C. Simmerling, R. E. Amaro and R. Freeman, GlycoGrip: Cell Surface-Inspired Universal Sensor for Betacoronaviruses, *ACS Cent. Sci.*, 2022, **8**(1), 22–42.

